<SEC-DOCUMENT>0001193125-18-072442.txt : 20180307
<SEC-HEADER>0001193125-18-072442.hdr.sgml : 20180307
<ACCEPTANCE-DATETIME>20180306211735
ACCESSION NUMBER:		0001193125-18-072442
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20180307
DATE AS OF CHANGE:		20180306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SCYNEXIS INC
		CENTRAL INDEX KEY:			0001178253
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562181648
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-207705
		FILM NUMBER:		18671744

	BUSINESS ADDRESS:	
		STREET 1:		101 HUDSON STREET
		STREET 2:		SUITE 3610
		CITY:			JERSEY CITY
		STATE:			NJ
		ZIP:			07302-6548
		BUSINESS PHONE:		201-884-5485

	MAIL ADDRESS:	
		STREET 1:		101 HUDSON STREET
		STREET 2:		SUITE 3610
		CITY:			JERSEY CITY
		STATE:			NJ
		ZIP:			07302-6548
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d540762d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>As Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-207705<BR> </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(To Prospectus
dated November&nbsp;16, 2015)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g540762g42k37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>17,751,500 Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants to
Purchase up to 21,301,800 Shares of Common Stock </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">We are offering
shares of our common stock. Each investor will also receive a warrant to purchase 0.75 of a share of our common stock at an exercise price of $1.85 per share (referred to as &#147;Series 1 warrants&#148;), and a warrant to purchase 0.45 of a share
of our common stock at an exercise price of $2.00 per share (referred to as &#147;Series 2 warrants&#148; and together with the Series 1 warrants, the &#147;warrants&#148;), for each share of common stock purchased. Subject to certain ownership
limitations, the warrants are immediately exercisable and expire (a)&nbsp;with respect to Series 1 warrants, 53 weeks from the date of issuance, and (b)&nbsp;with respect to the Series 2 warrants, on the five year anniversary of the date of
issuance. The shares of common stock and warrants are immediately separable and will be issued separately. Our common stock is quoted on The Nasdaq Global Market under the symbol &#147;SCYX.&#148; On March&nbsp;5, 2018, the last reported sale price
of our common stock was $1.69 per share. The sale price per share of common stock and underlying warrants is equal to the closing sale price of a share of common stock on March 5, 2018. We do not intend to list the warrants on The Nasdaq Global
Market, any other national securities exchange or any other nationally recognized trading system. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:11pt; font-family:Times New Roman"><B>Our business
and an investment in our securities involve significant risks. These risks are described under the caption &#147;<A HREF="#supptoc540762_3">Risk Factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-7</FONT> of this prospectus
supplement and in the documents incorporated by reference into this prospectus supplement. </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share and<BR>Accompanying<BR>Warrants (1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.6900</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,000,035</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Underwriting discount (2)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.1014</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,800,002</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><B>Proceeds, before expenses, to SCYNEXIS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1.5886</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>28,200,033</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The public offering price is $1.69 per share of common stock and accompanying warrants to purchase 0.75 of a share of common stock (Series 1 warrant) and 0.45 of a share of common stock (Series 2 warrant).
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for additional disclosure regarding underwriting commissions and expenses. </TD></TR></TABLE>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">The above summary of offering proceeds to us does not give effect to any exercise of the warrants being issued in this offering. </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Certain of our directors and executive officers have indicated an interest in purchasing in the aggregate up to 135,500 shares of our common
stock and accompanying warrants in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, these directors and executive officers may determine to purchase fewer
shares than they indicate an interest in purchasing or not to purchase any shares in this offering. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:3%; font-size:9pt; font-family:Times New Roman">Delivery of the shares of common stock
will be made through the book-entry facilities of The Depository Trust Company. Delivery of the warrants will be made by physical delivery. We anticipate that delivery of the shares of our common stock and warrants will be made on or about March 8,
2018, subject to customary closing conditions. </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole
Book-Running Manager </I></B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Guggenheim Securities </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Lead Manager </I></B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Needham &amp; Company </B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B><I>Co-Managers </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="40%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>Roth&nbsp;Capital&nbsp;Partners</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>CIM&nbsp;Securities,&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>National&nbsp;Securities&nbsp;Corporation</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is March 6, 2018. </B></P> <P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4" ALIGN="center"><B>PROSPECTUS SUPPLEMENT</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_6">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_8">DESCRIPTION OF THE SECURITIES WE ARE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_9">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_12">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">S-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_13">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc540762_14">ANNEX A &#151; FORM OF WARRANT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="4" ALIGN="center"><B>PROSPECTUS</B></TD>
<TD VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of the common stock and
warrants we are offering. The second part, the accompanying prospectus dated November&nbsp;16, 2015, gives more general information about our securities, some of which may not apply to this offering. You should read this prospectus supplement and
the accompanying prospectus, including the information incorporated by reference and any free writing prospectuses we have authorized for use in connection with this offering, in their entirety before making an investment decision. You should also
read and consider the information in the documents to which we have referred you in the sections of this prospectus supplement entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by
Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained or incorporated by reference in this prospectus supplement and the
accompanying prospectus, along with the information contained in any free writing prospectuses we have authorized for use in connection with this offering. We have not, and the underwriters have not, authorized anyone to provide you with different
or additional information. If the description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement. If any statement in one of these documents is
inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this prospectus supplement&#151;the statement in the document having the later date modifies or supersedes the earlier
statement. Under no circumstances should the delivery to you of this prospectus supplement and the accompanying prospectus or any sale made pursuant to this prospectus supplement create any implication that the information contained in this
prospectus supplement or the accompanying prospectus is correct as of any time after the respective dates of such information. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context requires otherwise, the words &#147;SCYNEXIS&#148;, &#147;the Company,&#148; &#147;we&#148;, &#147;us&#148; and
&#147;our&#148; refer to SCYNEXIS, Inc., and the term &#147;you&#148; refers to a prospective investor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and
the accompanying prospectus, including the information incorporated by reference into this prospectus supplement and the accompanying prospectus, include trademarks, service marks and trade names owned by us or others. All trademarks, service marks
and trade names included or incorporated by reference in this prospectus supplement and the accompanying prospectus or any related free writing prospectus are the property of their respective owners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering to sell, and seeking offers to buy, shares of common stock and warrants only in jurisdictions where offers and sales are
permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this
prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement and the accompanying prospectus outside
the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and
the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We obtained the industry and market data in this prospectus supplement and the accompanying prospectus from our own research as well as from
industry and general publications, surveys and studies conducted by third parties. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions
and estimates of our future performance and the future performance of the industry in which we operate is necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors&#148;
and elsewhere in this prospectus supplement, the accompanying prospectus and documents incorporated by reference in this prospectus supplement and the accompanying prospectus. These and other factors could cause results to differ materially from
those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere or incorporated by reference in this prospectus supplement and
accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering; it may not contain all of the information that is important to you. This prospectus supplement and the accompanying prospectus
include information about the shares and warrants we are offering as well as information regarding our business and financial data. You should read this prospectus supplement and the accompanying prospectus, including the information incorporated by
reference and any free writing prospectuses we have authorized for use in connection with this offering, in their entirety. Investors should carefully consider the information set forth under &#147;Risk Factors&#148; in this prospectus supplement
and incorporated by reference from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCYNEXIS, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SCYNEXIS, Inc. is a biotechnology company committed to positively impacting&nbsp;the lives&nbsp;of patients suffering from <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> and often life-threatening infections by delivering innovative anti-infective therapies. We are developing our lead product candidate, <FONT
STYLE="white-space:nowrap">SCY-078,</FONT> as the first representative of a novel oral and intravenous (IV)&nbsp;triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive
candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). <FONT STYLE="white-space:nowrap">SCY-078</FONT> is a structurally distinct glucan synthase inhibitor that has been shown to be
effective<I>&nbsp;in vitro</I>&nbsp;and<I>&nbsp;in vivo</I>&nbsp;against a broad range of&nbsp;human fungi pathogens such as<I>&nbsp;Candida</I> and <I>Aspergillus</I>&nbsp;species, including multidrug-resistant strains, as well
as<I>&nbsp;Pneumocystis </I>species.<I> Candida</I> and<I> Aspergillus</I> species are the fungi responsible for approximately 85% of all invasive fungal infections in the United States (U.S.) and Europe. To date, we have characterized the
pharmacokinetics and safety profile of oral and IV formulations of <FONT STYLE="white-space:nowrap">SCY-078</FONT> in multiple Phase 1 studies. In a Phase 2 study, evaluating oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> as a step-down
therapy in patients with invasive candidiasis, we confirmed that oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> achieved the intended plasma exposure for efficacy and was well-tolerated. In another Phase 2 <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study, evaluating oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> in patients with VVC, we observed numerically higher clinical cure rates at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">test-of-cure</FONT></FONT> visit and fewer recurrences of infection at the four-month <FONT STYLE="white-space:nowrap">follow-up</FONT> when compared to oral fluconazole, the standard of care (SoC). We applied to the U.S.
Food and Drug Administration (FDA) for, and received, the designation of the oral tablet and IV formulations of <FONT STYLE="white-space:nowrap">SCY-078</FONT> for invasive candidiasis and invasive aspergillosis as Qualified Infectious Disease
Product, or QIDP, under the Generating Antibiotic Incentives Now Act, or GAIN Act. We also applied to the FDA for, and were granted, Fast Track designation for <FONT STYLE="white-space:nowrap">SCY-078</FONT> for these indications. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Our Platform of Indications </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We continue to accelerate and expand our clinical programs, leveraging the versatility of the <FONT STYLE="white-space:nowrap">SCY-078</FONT>
platform, including the potential for oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> to be a suitable treatment for indications with significant unmet medical needs and considerable commercial opportunity. The following table summarizes the
indications we are currently seeking, anticipated NDA submission timing and estimated peak sales in the United States: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g540762g27k51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>VVC&#151;Our most advanced stage of clinical development, targeting both acute and recurrent infections.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients in a Phase 2b dose-finding study of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> for the
treatment of VVC (DOVE study). The DOVE study is a randomized, multicenter, double-blind, active-controlled, dose-finding study designed to evaluate the safety and efficacy of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> versus oral
fluconazole in adult female patients. Approximately 180 patients with moderate to severe acute VVC are being randomized to one of five different regimens of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> or oral fluconazole, the current
standard of care (SoC). Efficacy will be measured by the percentage of patients with clinical cure (complete resolution of signs and symptoms) at the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">test-of-cure</FONT></FONT> visit
at day 10 (primary endpoint) and at a <FONT STYLE="white-space:nowrap">follow-up</FONT> visit on day 25. Mycological eradication (negative fungal culture) will also be evaluated at the same time points. Robust enrollment in the study has been
maintained and we expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> results for this study in <FONT STYLE="white-space:nowrap">mid-2018.</FONT> Upon successful completion of the DOVE study and following an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">End-of-Phase</FONT></FONT> 2 meeting with the FDA, we plan to study the single dose regimen selected from this study in a subsequent Phase 3 program, initiating in the fourth quarter of
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Invasive Candidiasis&#151;Path forward established for IV program of <FONT STYLE="white-space:nowrap">SCY-078,</FONT> with
clinical trials to initiate in the third quarter of 2018 with an improved IV formulation. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed in&nbsp;March 2017,
the&nbsp;FDA&nbsp;required&nbsp;us&nbsp;to hold the initiation of any new clinical studies with the IV formulation of <FONT STYLE="white-space:nowrap">SCY-078</FONT> following the review of three <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mild-to-moderate</FONT></FONT> inflammation-related thrombotic events observed in healthy volunteers receiving the highest dose level of a cyclodextrin-based IV formulation of
<FONT STYLE="white-space:nowrap">SCY-078</FONT> in a Phase 1 study. Based on subsequent interactions with the FDA, we completed a </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
broad range of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities designed to identify the underlying cause of the thrombotic events and to evaluate the optimal administration
regimen for the cyclodextrin-based IV formulation of <FONT STYLE="white-space:nowrap">SCY-078.</FONT> Several <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies showed that <FONT STYLE="white-space:nowrap">SCY-078</FONT> does not affect
blood coagulation by itself, providing supporting evidence that the thrombotic events associated with the administration of the cyclodextrin-based IV formulation were triggered by vascular endothelium inflammation at the site of infusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In parallel, we continued our pursuit of alternative IV formulations and accelerated the development of a new formulation based on liposomal
technology that has been successfully used to improve systemic tolerability of other commercially available IV formulations, including IV antifungals. In comparing the cyclodextrin-based IV formulation <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">head-to-head</FONT></FONT> against the liposomal IV formulation of <FONT STYLE="white-space:nowrap">SCY-078</FONT> in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> evaluations, the liposomal formulation showed a
superior profile for infusion-related tolerability and vascular inflammation. Based on these initial <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, we believe that the liposomal IV formulation may offer significant clinical benefits
over the cyclodextrin-based IV formulation and, therefore, we decided to focus our efforts on the advancement of the liposomal IV formulation of <FONT STYLE="white-space:nowrap">SCY-078.</FONT> This decision was discussed with the FDA and a path
forward was established. <FONT STYLE="white-space:nowrap">IND-enabling</FONT> <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies with the liposomal formulation are ongoing, and we anticipate initiating a Phase 1 study in healthy volunteers
with the liposomal IV formulation of <FONT STYLE="white-space:nowrap">SCY-078</FONT> in the third quarter of 2018. Upon successful completion of the Phase 1 study and pending FDA&#146;s review, we plan to initiate a Phase 2b <FONT
STYLE="white-space:nowrap">IV-Oral</FONT> step-down study of <FONT STYLE="white-space:nowrap">SCY-078</FONT> in invasive candidiasis patients with the liposomal IV and oral formulations of <FONT STYLE="white-space:nowrap">SCY-078</FONT> in the
fourth quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Invasive <FONT STYLE="white-space:nowrap">Aspergillosis&#151;SCY-078</FONT> in combination with standard of
care may represent a significant opportunity to improve outcomes for this high-mortality infection. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on promising pre-clinical
data with combination use of <FONT STYLE="white-space:nowrap">SCY-078</FONT> with SoC vs. <I>Aspergillus</I> spp., we plan to initiate a Phase 2 study of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> in patients with invasive aspergillosis in
the third quarter of 2018. This initial study is planned as a randomized, double-blind trial with the objective of assessing the safety and efficacy of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> in combination with azole therapy, the SoC
for this indication, compared to SoC alone. We believe that <FONT STYLE="white-space:nowrap">SCY-078&#146;s</FONT> broad activity against<I>&nbsp;Aspergillus</I>&nbsp;spp., including <FONT STYLE="white-space:nowrap">azole-resistant</FONT> strains,
along with its minimal drug-drug interactions, high tissue penetration into the lungs and oral formulation allowing for long-term administration, make it an ideal candidate for use as combination therapy to provide improved outcomes vs. SoC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Refractory Invasive Fungal Infections&#151;Potential for streamlined development pathway. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently enrolling patients in the FURI study, a global, open-label study in which oral
<FONT STYLE="white-space:nowrap">SCY-078</FONT> is being administered to patients with invasive fungal infections that are refractory to, or that are intolerant of, standard therapy (azoles, echinocandins and/or polyenes). <FONT
STYLE="white-space:nowrap">Twenty-four</FONT> sites in the U.S. and Europe are now active in this study and enrollment is progressing. We also initiated the CARES study, a global, open-label study of oral
<FONT STYLE="white-space:nowrap">SCY-078</FONT> for the treatment of<I>&nbsp;Candida auris</I>&nbsp;infections.<I>&nbsp;Candida auris</I>&nbsp;has been classified by the Centers for Disease Control and Prevention (CDC) as a serious public health
threat, as it is multidrug-resistant, has resulted in high mortality rates (up to 60%) and can be spread from patients (and surfaces) to patients, resulting in hospital outbreaks.&nbsp;The CARES study is intended to provide rapid access to oral <FONT
STYLE="white-space:nowrap">SCY-078</FONT> for patients suffering from this life-threatening infection. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The open-label designs of the FURI
and CARES studies allow for evaluation of the data on an interim basis to further inform subsequent regulatory steps of the development program. We believe that compelling data from the FURI and/or CARES studies could allow <FONT
STYLE="white-space:nowrap">SCY-078</FONT> to become eligible for the regulatory Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) potentially resulting in an initial New Drug Application (NDA) based on streamlined development.
We plan to continue to advance enrollment in the FURI and CARES studies, both in the U.S. and globally, with preliminary data review planned for the fourth quarter of 2018. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Key milestones </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe we will achieve the following key milestones in 2018: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to complete enrollment and announce <FONT STYLE="white-space:nowrap">top-line</FONT> study results of the DOVE Phase 2b study of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> as a treatment for VVC in <FONT
STYLE="white-space:nowrap">mid-2018</FONT> and initiate the Phase 3 VVC program in the fourth quarter of 2018 following an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> 2 meeting with the FDA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to initiate the Phase 1 clinical trial to evaluate the safety and tolerability of the liposomal IV formulation of <FONT STYLE="white-space:nowrap">SCY-078</FONT> in healthy volunteers in the third quarter of 2018. Upon
successful completion of the Phase&nbsp;1 study, initiate a Phase 2b clinical trial designed to evaluate IV/oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> for the treatment of invasive candidiasis in the fourth quarter of 2018;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to initiate a Phase 2 study of oral <FONT STYLE="white-space:nowrap">SCY-078</FONT> in combination with current standard of care as a treatment for invasive aspergillosis in the third quarter of 2018; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to continue to advance enrollment in both the FURI and CARES studies, both in the U.S. and globally, with preliminary data review planned for the fourth quarter of 2018. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key
elements of our strategy include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to further develop <FONT STYLE="white-space:nowrap">SCY-078</FONT> and obtain regulatory approval in major commercial markets for our key initial indications: VVC (acute and recurrent), invasive candidiasis and invasive
aspergillosis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to commercialize <FONT STYLE="white-space:nowrap">SCY-078</FONT> for selected indications in the U.S. through a dedicated commercial team, including field force; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to contract with commercial partners to develop and commercialize <FONT STYLE="white-space:nowrap">SCY-078</FONT> outside of the U.S.; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to assess external opportunities to expand our clinical pipeline; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to leverage our strong scientific team to pursue the development of other internal proprietary compounds. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Preliminary Financial Data </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2017, we had approximately $43.9&nbsp;million in cash, cash equivalents and short-term investments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preliminary financial data included in this prospectus supplement has been prepared by, and is the responsibility of, SCYNEXIS,
Inc.&#146;s management. Deloitte&nbsp;&amp; Touche LLP has not audited, reviewed, compiled, or performed any procedures with respect to the preliminary financial data. Accordingly, Deloitte&nbsp;&amp; Touche LLP does not express an opinion or any
other form of assurance with respect thereto. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors Associated With Our Business </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this
prospectus supplement summary and other risks set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the Securities and Exchange Commission, or SEC, on March&nbsp;13,
2017, especially in the section entitled &#147;Risk Factors,&#148; which is incorporated by reference in this prospectus supplement or accompanying prospectus. You should read these risk factors before you invest in our common stock. In particular,
these risks include, but are not limited to, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to curtail our losses and reach profitability
is unproven, and we may never achieve or sustain profitability; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may continue to require substantial additional capital, and if we are unable to raise capital when needed we would be forced to delay, reduce or eliminate our development program for
<FONT STYLE="white-space:nowrap">SCY-078;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We cannot be certain that <FONT STYLE="white-space:nowrap">SCY-078</FONT> will receive regulatory approval, and without regulatory approval we will not be able to market <FONT STYLE="white-space:nowrap">SCY-078.</FONT>
Regulatory approval is a lengthy, expensive and uncertain process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Although both the oral and IV formulations of <FONT STYLE="white-space:nowrap">SCY-078</FONT> have been granted Qualified Infectious Disease Product status and Fast Track designation for invasive candidiasis and
invasive aspergillosis, this does not guarantee that the length of the FDA review process will be significantly shorter than otherwise, or that <FONT STYLE="white-space:nowrap">SCY-078</FONT> will ultimately be approved by the FDA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for
<FONT STYLE="white-space:nowrap">SCY-078</FONT> or any future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we or our current or potential
future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited experience in conducting clinical trials and have never submitted an NDA before, and we may be unable to do so for <FONT STYLE="white-space:nowrap">SCY-078</FONT> or any future product candidate we may
seek to develop; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The environment in which our regulatory submissions may be reviewed changes over time, which may make it more difficult to obtain regulatory approval of any of our product candidates we may seek to develop or
commercialize; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Even if we are able to obtain regulatory approval of our product candidates, there is no guarantee that payors, physicians or patients will perceive the benefits of these product candidates as we do, or that they will
be commercially successful. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were originally incorporated in Delaware in November 1999 as ScyRex, Inc. We subsequently changed our name to SCYNEXIS Chemistry&nbsp;&amp;
Automation, Inc. in April 2000 and to SCYNEXIS, Inc. in June 2002. Our principal executive offices are located at 101 Hudson Street, Suite 3610, Jersey City, NJ 07302-6548, and our telephone number is (201) 884-5485. Our website address is
<I>www.scynexis.com</I>. The information contained on our website is not incorporated by reference into this prospectus supplement or related prospectus, and you should not consider any information contained on, or that can be accessed through, our
website as part of this prospectus supplement or related prospectus or in deciding whether to purchase our securities. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us: </P></TD>
<TD>17,751,500 shares, plus 21,301,800 shares of our common stock underlying the warrants offered in this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Warrants Offered by Us in this Offering: </P></TD>
<TD>Warrants to purchase up to 21,301,800 shares of common stock. For each share of common stock purchased, each investor will receive a warrant to purchase 0.75 of a share of our common stock (referred to as &#147;Series 1 warrants&#148;), and a
warrant to purchase 0.45 of a share of our common stock (referred to as &#147;Series 2 warrants&#148; and together with the Series 1 warrants, the &#147;warrants&#148;). The Series 1 warrant will have an exercise price of $1.85 per share, and the
Series&nbsp;2 warrant will have an exercise price of $2.00 per share. Subject to certain ownership limitations, the warrants are immediately exercisable and expire (a)&nbsp;with respect to Series 1 warrants, 53&nbsp;weeks from the date of issuance,
and (b)&nbsp;with respect to the Series 2 warrants, on the five year anniversary of the date of issuance. The form of warrant is attached as Annex A to this prospectus supplement. This prospectus supplement also relates to the offering of the shares
of common stock issuable upon exercise of the warrants. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering: </P></TD>
<TD>46,087,336 shares </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds: </P></TD>
<TD>We currently expect to use the net proceeds from this offering for general corporate purposes, including expansion of our research and development programs, <FONT STYLE="white-space:nowrap">build-out</FONT> of commercial infrastructure, capital
expenditures and working capital. See &#147;Use of Proceeds&#148;. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors: </P></TD>
<TD>You should read the &#147;Risk Factors&#148; section of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase shares of our
common stock and accompanying warrants. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market Symbol: </P></TD>
<TD>&#147;SCYX&#148;. We do not intend to list the warrants on The Nasdaq Global Market, any other national securities exchange or any other nationally recognized trading system. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of our shares of common stock outstanding after this offering is based on 28,335,836 shares of common stock outstanding as of
September&nbsp;30, 2017, and excludes the shares of common stock issuable upon exercise of the warrants being offered by us in this offering and also excludes, as of September&nbsp;30, 2017, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,888,146 shares of common stock issuable upon the exercise of stock options outstanding with a weighted average exercise price of $5.83 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,355,218 shares of common stock issuable upon the exercise of warrants outstanding with a weighted average exercise price of $3.16; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">687,230 shares of common stock available for future grants under our equity incentive plans; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">83,617 of common stock available for future issuance under our employee stock purchase plan. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Any investment in our securities involves a high degree of risk. You should consider carefully the risks described below and discussed
under the section captioned &#147;Risk Factors&#148; contained in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the Securities and Exchange Commission, or SEC, on
March&nbsp;13, 2017, which is incorporated by reference in this prospectus supplement in their entirety, together with other information in this prospectus supplement and accompanying prospectus, and the information and documents incorporated by
reference in this prospectus supplement, and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest in our securities. If any of the following events actually occur, our
business, operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock and the value of the warrants to decline, and you may lose all or part of your
investment. The risks below and incorporated by reference in this prospectus supplement are not the only ones we face. Additional risks not currently known to us or that we currently deem immaterial may also affect our business operations. Please
also read carefully the section below entitled &#147;Special Note Regarding Forward-Looking Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Risks Associated with
our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks. You should read these risks before you invest in our common stock. In
particular, our risks include, but are not limited to, the following and other risks set forth in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the Securities and
Exchange Commission, or SEC, on March&nbsp;13, 2017, <I></I>which is incorporated by reference here: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There is no established public trading market for the warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the warrants on any national
securities exchange or other nationally recognized trading system, including The Nasdaq Global Market. Without an active market, the liquidity of the warrants will be limited. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales. As a result, our ability to curtail our losses and reach profitability
is unproven, and we may never achieve or sustain profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may continue to require substantial additional capital, and if we are unable to raise capital when needed we would be forced to delay, reduce or eliminate our development program for
<FONT STYLE="white-space:nowrap">SCY-078;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We cannot be certain that <FONT STYLE="white-space:nowrap">SCY-078</FONT> will receive regulatory approval, and without regulatory approval we will not be able to market <FONT STYLE="white-space:nowrap">SCY-078.</FONT>
Regulatory approval is a lengthy, expensive and uncertain process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Although both the oral and IV formulations of <FONT STYLE="white-space:nowrap">SCY-078</FONT> have been granted Qualified Infectious Disease Product status and Fast Track designation for invasive candidiasis and
invasive aspergillosis, this does not guarantee that the length of the FDA review process will be significantly shorter than otherwise, or that <FONT STYLE="white-space:nowrap">SCY-078</FONT> will ultimately be approved by the FDA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Delays in the commencement, enrollment and completion of clinical trials could result in increased costs to us and delay or limit our ability to obtain regulatory approval for
<FONT STYLE="white-space:nowrap">SCY-078</FONT> or any future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we or our current or potential
future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited experience in conducting clinical trials and have never submitted an NDA before, and we may be unable to do so for <FONT STYLE="white-space:nowrap">SCY-078</FONT> or any future product candidate we may
seek to develop; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The environment in which our regulatory submissions may be reviewed changes over time, which may make it more difficult to obtain regulatory approval of any of our product candidates we may seek to develop or
commercialize; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Even if we are able to obtain regulatory approval of our product candidates, there is no guarantee that payors, physicians or patients will perceive the benefits of these product candidates as we do, or that they will
be commercially successful. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Additional Risks Relating To The Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield
a significant return. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Management will have broad discretion over the use of proceeds from this offering. The net proceeds from
this offering will be used for working capital and general corporate purposes, which may include, among other things, funding research and development, clinical trials, vendor payables, potential regulatory submissions, hiring additional personnel
and capital expenditures. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses or products; however, we have no current commitments or obligations to do
so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as
part of your investment decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary
substantially from their currently intended use. The net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>You will experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common
stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on the public offering of 17,751,500 shares at the price of $1.69 per share and accompanying warrants, and without
deducting underwriting discounts and commissions but after deducting estimated offering expenses payable by us, and based on a net tangible book value of our common stock as of September&nbsp;30, 2017, as adjusted to give effect to this offering, if
you purchase shares of common stock and accompanying warrants in this offering, you will suffer immediate and substantial dilution of $0.50 per share in the net tangible book value of common stock. The exercise of our outstanding stock options and
warrants could result in further dilution of your investment. See the section entitled &#147;Dilution&#148; below for a more detailed illustration of the dilution you would incur if you participate in this offering. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or
exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors
in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities convertible or
exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On April&nbsp;11, 2016, we entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald&nbsp;&amp; Co. (the &#147;ATM
Agreement&#148;), under which we may offer and sell our common stock having aggregate sales proceeds of up to $40&nbsp;million from time to time through our sales agent. As of December 31, 2017, common
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock for aggregate gross proceeds of $24.1 million remained available to be sold under this facility, subject to certain conditions as specified in the ATM Agreement. In connection with this
offering, we have agreed not to utilize the ATM Agreement from the date of this prospectus supplement continuing through and including the date 90 days after the date of this prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future, stockholders must rely on
appreciation of the value of our common stock for any return on their investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on
our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms
of any existing or future debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the foreseeable future.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>There is no public market for the warrants to purchase shares of our common stock being offered in this offering. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no established public trading market for the warrants being offered in this offering, and we do not expect a market to develop. In
addition, we do not intend to apply to list the warrants on any national securities exchange or other nationally recognized trading system, including The Nasdaq Global Market. Without an active market, the liquidity of the warrants will be limited.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and accompanying prospectus and the documents we have filed with the SEC that are incorporated by reference contain
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate
to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future
results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop <FONT STYLE="white-space:nowrap">SCY-078,</FONT> including an IV formulation of <FONT STYLE="white-space:nowrap">SCY-078;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully implement and complete enrollment in our Phase 2 invasive candidiasis study with the oral formulation of <FONT STYLE="white-space:nowrap">SCY-078;</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the benefits we will obtain from the oral and IV form of <FONT STYLE="white-space:nowrap">SCY-078</FONT> having been designated as a QIDP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain FDA approval of <FONT STYLE="white-space:nowrap">SCY-078;</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the devotion of our resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expected uses of the net proceeds to us from any specific offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expected costs of studies and when they will begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to scale up manufacturing to commercial scale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reliance on third parties to conduct our clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reliance on third-party contract manufacturers to manufacture and supply commercial supplies of <FONT STYLE="white-space:nowrap">SCY-078</FONT> for us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the marketing of <FONT STYLE="white-space:nowrap">SCY-078</FONT> should we receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial performance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments and projections relating to our competitors or our industry. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you
can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148;
&#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based
on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#147;Risk
Factors&#148; contained in this prospectus supplement, in any free writing prospectuses we may authorize for use in connection with a specific offering, and in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> which
is incorporated by reference into this prospectus supplement and accompanying prospectus their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document containing the applicable
statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over time means that actual
events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus supplement and accompanying prospectus together with the documents we have filed with the SEC that are incorporated by reference and
any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking
statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of the shares of common stock and the accompanying warrants that we are offering will be
approximately $27.8 million, after deducting the underwriting discount and estimated offering expenses payable by us and excluding the proceeds, if any, from the exercise of the warrants issued pursuant to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will retain broad discretion over the use of the net proceeds from this offering. We currently expect to use the net proceeds from this
offering for working capital and general corporate purposes, which may include, among other things, funding research and development, clinical trials, vendor payables, potential regulatory submissions, hiring additional personnel and capital
expenditures. We may also use a portion of the net proceeds to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in complementary businesses or products; however, we have no current commitments or obligations to do so. Amounts
and timing of our actual expenditures will depend on numerous factors, including our development and commercialization efforts, as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net
proceeds to be used for the purposes described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. Pending the uses described above, we
plan to invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our capitalization as of September&nbsp;30, 2017: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On an actual basis; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as adjusted basis to give effect to the receipt of the estimated net proceeds of $27.8 million from the sale of the common stock and warrants in this offering, after deducting the underwriting discount and
estimated offering expenses payable by us as described under &#147;Use of Proceeds&#148; and excluding the proceeds, if any, from the exercise of the warrants issued pursuant to this offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read the data set forth in the table below in conjunction with (a)&nbsp;our financial statements, including the related notes, and
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016, and (b)&nbsp;our
condensed financial statements, including the related notes, and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; from our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the quarterly period ended September&nbsp;30, 2017, which are incorporated by reference into this prospectus supplement and the accompanying prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of September&nbsp;30, 2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:176.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>(In thousands, except share and per share
amounts)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,709</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#146; equity:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock, par value of $0.001 per share, 5,000,000 shares authorized; 0 shares issued and
outstanding, actual and as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, par value of $0.001 per share, 125,000,000 shares authorized; 28,335,836 shares
issued and outstanding, actual, 46,087,336 shares issued and outstanding as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">224,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(197,660</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">27,264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,089</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of our shares of common stock outstanding is based on 28,335,836 shares of common stock outstanding
as of September&nbsp;30, 2017, and excludes the shares of common stock issuable upon exercise of the warrants being offered by us in this offering and also excludes, as of September&nbsp;30, 2017, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,888,146 shares of common stock issuable upon the exercise of stock options outstanding with a weighted average exercise price of $5.83 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,355,218 shares of common stock issuable upon the exercise of warrants outstanding with a weighted average exercise price of $3.16; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">687,230 shares of common stock available for future grants under our equity incentive plans; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">83,617 of common stock available for future issuance under our employee stock purchase plan. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock, your interest will be diluted immediately to the extent of the difference between the public offering price
and the adjusted net tangible book value per share of our common stock after this offering. Net tangible book value on September&nbsp;30, 2017, was approximately $26.9&nbsp;million, or $0.95 per share. &#147;Net tangible book value&#148; is total
assets minus the sum of liabilities and intangible assets. &#147;Net tangible book value per share&#148; is net tangible book value divided by the total number of shares outstanding. Net tangible book value per share after this offering gives effect
to the sale of 17,751,500 shares of our common stock in this offering at an offering price of $1.69 per share and accompanying warrants, after deducting offering commissions and estimated expenses payable by us. Our as adjusted net tangible book
value as of September&nbsp;30, 2017, after giving effect to this offering as described above, would have been approximately $54.7 million, or $1.19 per share of common stock. This represents an immediate increase in net tangible book value of $0.24
per share to our existing stockholders and an immediate dilution in net tangible book value of $0.50 per share to investors participating in this offering. The following table illustrates this dilution per share to investors participating in this
offering:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering price per share and accompanying warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors in offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share after giving effect to the offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of our shares of common stock outstanding is based on 28,335,836 shares of common stock outstanding
as of September&nbsp;30, 2017, and excludes the shares of common stock issuable upon exercise of the warrants being offered by us in this offering and also excludes, as of September&nbsp;30, 2017, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,888,146 shares of common stock issuable upon the exercise of stock options outstanding with a weighted average exercise price of $5.83 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4,355,218 shares of common stock issuable upon the exercise of warrants outstanding with a weighted average exercise price of $3.16; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">687,230 shares of common stock available for future grants under our equity incentive plans; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">83,617 of common stock available for future issuance under our employee stock purchase plan. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any of the outstanding options and warrants are exercised, there will be further dilution to new investors. In addition, we
may choose to raise additional capital due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of
equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_8"></A>DESCRIPTION OF THE SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering shares of our common stock and warrants to purchase shares of our common stock (and the shares of our common stock issuable
from time to time upon exercise of the offered warrants). The common stock and warrants will be issued separately. The common stock offered by this prospectus supplement and the accompanying prospectus is described in the accompanying prospectus
under the heading &#147;Description of Capital Stock.&#148; The warrants offered by this prospectus supplement and the accompanying prospectus are described immediately below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Form.</I> The warrants will
be issued as individual warrant agreements to the investors. The form of warrant is attached as Annex A to this prospectus supplement. We will issue two series of warrants, the Series 1 warrants and the Series 2 warrants, which are collectively
referred to as the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercisability.</I> The warrants are exercisable beginning on the date of issuance, and at any time up to
the date 53 weeks from the date of issuance in the case of the Series 1 warrants, and the five year anniversary of the date of issuance in the case of the Series 2 warrants. The warrants will be exercisable, at the option of each holder, in whole or
in part by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as discussed below). No fractional shares
of common stock will be issued in connection with the exercise of a warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the market value of a share of common stock. The holder
will not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the warrants, provided that such percentage may be increased to up to 14.99% by the holder upon 61 days&#146; notice. A particular holder may have a higher
percentage ownership if circumstances require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Failure to Timely Deliver Shares.</I> If we fail to deliver to the investor a
certificate representing shares issuable upon exercise of a warrant by the second trading day after the exercise date as required by the warrant, and if the investor purchases the shares of our common stock after that second trading day to deliver
in satisfaction of a sale by the investor of the underlying warrant shares that the investor anticipated receiving from us, then, within three trading days of receipt of the investor&#146;s request, we, at the investor&#146;s discretion, will either
(i)&nbsp;pay cash to the investor in an amount equal to the investor&#146;s total purchase price (including brokerage commissions, if any) for the shares of common stock purchased less the exercise price (as described below), or the <FONT
STYLE="white-space:nowrap">buy-in</FONT> price, at which point our obligation to deliver the warrant (and to issue the underlying common stock) will terminate, or (ii)&nbsp;promptly honor our obligation to deliver to the investor a certificate or
certificates representing the underlying common stock and pay cash to the investor in an amount equal to the excess (if any) of the <FONT STYLE="white-space:nowrap">buy-in</FONT> price over the product of (A)&nbsp;the number of shares of common
stock, times (B)&nbsp;the per share closing price of our common stock on the date of the event giving rise to our obligation to deliver the certificate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Cashless Exercise.</I> In the event that a registration statement covering shares of common stock underlying the warrants is not available
for either registration of such shares of common stock underlying the warrants or the resale of such underlying shares, the holder may, in its sole discretion, exercise the warrant in whole or in part and, in lieu of making the cash payment
otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, elect instead to receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the warrant.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exercise Price.</I> Each Series 1 warrant represents the right to purchase 0.75 of a share of common stock at an exercise price equal
to $1.85 per share, subject to adjustment as described below, and each Series 2 warrant represents the right to purchase 0.45 of a share of common stock at an exercise price of $2.00 per share, subject
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to adjustment and described below. The exercise prices are subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations,
reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Governing Law.</I> The warrant is governed by New York law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Transferability.</I> Subject to applicable laws, the warrants may be offered for sale, sold, transferred or assigned without our consent.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Exchange Listing.</I> There is no public trading market for the warrants, and we do not expect a market to develop. In addition, we do
not intend to apply for listing of the warrants on any securities exchange or other trading system.<I>&nbsp;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Fundamental
Transactions</I>. If we consummate any merger, consolidation, sale or other reorganization event in which our common stock is converted into or exchanged for securities, cash or other property, or if we consummate certain sales or other business
combinations, then at the election of the holder, (a)&nbsp;we (or any successor entity) will purchase the warrants from the holders for cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of such warrants on the
date of such fundamental transaction, as more completely described in the warrant or (b)&nbsp;the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the
holders would have received had they exercised the warrants immediately prior to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment and Waiver.</I> Except as
otherwise provided in the warrant, the warrant may only be amended by us and we may take any action prohibited by the warrant, or omit to perform any act required to be performed under the warrant, only if we obtained the written consent of the
holders of warrants representing at least a majority of shares of common stock underlying the warrants then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Rights as a
Stockholder.</I> Except as otherwise provided in the warrants or by virtue of such holder&#146;s ownership of shares of our common stock, the holder of a warrant does not have the rights or privileges of a holder of our common stock, including any
voting rights, until the holder exercises the warrant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_9"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, dated March 6, 2018, among us and Guggenheim Securities, LLC as
the representative of the underwriters named below and the sole book-running manager of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the
respective number of shares of our common stock and accompanying Series 1 warrants and Series 2 warrants at the public offering price, less the underwriting discount and commissions, as set forth on the cover page of this prospectus supplement, and
as shown opposite such underwriters name below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:61.95pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER OF<BR>SHARES<BR>UNDERLYING<BR>SERIES&nbsp;1<BR>WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER OF<BR>SHARES<BR>UNDERLYING<BR>SERIES&nbsp;2<BR>WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,781,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,585,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,751,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Needham &amp; Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,597,635</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,198,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">718,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright &amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Roth Capital Partners, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,242,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">931,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">559,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CIM Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">National Securities Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">443,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332,840</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,751,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,313,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,988,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the several underwriters are subject to certain
conditions precedent such as the receipt by the underwriters of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the
shares of common stock and warrants if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be
terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to
make in respect of those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our directors and executive officers have indicated an interest in purchasing in the
aggregate up to 135,500 shares of our common stock and accompanying warrants in this offering at the public offering price. However, because indications of interest are not binding agreements or commitments to purchase, these directors and executive
officers may determine to purchase fewer shares than they indicate an interest in purchasing or not to purchase any shares in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of common stock is being sold together with a Series 1 warrant to purchase 0.75 of a share of our common stock and a Series 2
warrant to purchase 0.45 of a share of our common stock. The shares of common stock and warrants will be issued separately. There is no market through which the warrants may be sold and purchasers may not be able to resell the warrants purchased
under this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of common stock and warrants subject to their acceptance of
the shares of common stock and warrants from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
underwriters have advised us that they propose to offer the shares of common stock and warrants to the public at the price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less
a concession not in excess of $0.06084 per share of common stock and related warrants. After the offering, the public offering price, the concession to dealers or any other term of the offering </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be changed by the representative. No such change will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting discounts and commissions are equal to the public offering price per share of common stock less the amount paid by the
underwriters to us per share of common stock and related warrants. The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in
connection with this offering. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share<BR>and<BR>Related<BR>Warrants</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.6900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,000,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.1014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.5886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,200,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $375,000, which includes reimbursements to the underwriters for certain expenses they incurred in connection with this offering in an amount up to $100,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to certain <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, we and our officers and directors have agreed, subject to
specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer to sell, contract to sell, effect any short sale, pledge, transfer, establish a &#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the
Exchange Act, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise dispose of, or enter into any swap, hedge or similar arrangement that transfers, in whole or in part, the economic risk of ownership of, any shares of common stock, options or warrants to acquire shares of
common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any shares of common stock, options or warrants to acquire shares of common stock, or
securities exchangeable or exercisable for or convertible into shares of common stock, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce any intention to do any of the foregoing </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">for a period of 90 days after the date of this
prospectus without the prior written consent of the representative, subject to specified exceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This restriction terminates after
the close of trading of the common stock on and including the 90th day after the date of this prospectus. The representative may, in its sole discretion and at any time or from time to time before the termination of the <FONT
STYLE="white-space:nowrap">90-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our stockholders
who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have
advised us that, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in
connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. Establishing short sales positions may
involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the
underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the
underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or
preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the
underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have
not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters make any representation or prediction as to
the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued
at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or through online services maintained
by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of
common stock and warrants for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the
information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not
be relied upon by investors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their respective affiliates are full service financial institutions engaged in various activities, which may
include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their respective affiliates have, from time to time, performed, and may in the future perform, various
commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters and certain of their respective affiliates may make or hold a
broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and
securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with
their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our
securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered hereby. The underwriters and certain of their
respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend
to clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Residents of Canada </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold only to purchasers purchasing as principal that are both &#147;accredited investors&#148; as defined in National
Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus and Registration Exemptions and &#147;permitted clients&#148; as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions
and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from the prospectus requirements and in compliance with the registration requirements of applicable securities laws. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended, which we refer to as the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to
(d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment
or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective
Investors in the EEA </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive,
which we refer to as a Relevant Member State, an offer to the public of any shares of common stock that are the subject of the offering contemplated by this prospectus may not be made in that Relevant Member State, except that an offer to the public
in that Relevant Member State of any shares may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">to legal entities which are authorized or regulated to operate in the financial markets or, if not so authorized or regulated, whose corporate purpose is solely to invest in securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which has two or more of (1)&nbsp;an average of at least 250 employees during the last financial year; (2)&nbsp;a total balance sheet of more than &#128;43,000,000 and (3)&nbsp;an annual net turnover
of more than &#128;50,000,000, as shown in its last annual or consolidated accounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">by the underwriters to fewer than 100 natural or legal persons (other than &#147;qualified investors&#148; as defined in the Prospectus Directive) subject to obtaining the prior consent of the representative for any
such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such
offer of shares shall result in a requirement for the publication by us or any representative of a prospectus pursuant to Article 3 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any person making or intending to make any offer of shares within the EEA should only do so in circumstances in which no obligation arises for
us or any of the underwriters to produce a prospectus for such offer. Neither we nor the underwriters have authorized, nor do they authorize, the making of any offer of shares through any financial intermediary, other than offers made by the
underwriters which constitute the final offering of shares contemplated in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, and your
representation below, the expression an &#147;offer to the public&#148; in relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to
be offered so as to enable an investor to decide to purchase any shares, as the same may be varied in that Relevant Member State by any measure implementing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Prospectus Directive in that Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC and includes any relevant implementing measure in each
Relevant Member State. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member State who receives any communication in respect of, or who acquires any shares
under, the offer of shares contemplated by this prospectus will be deemed to have represented, warranted and agreed to and with us and each underwriter that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">in the case of any shares acquired by it as a financial intermediary, as that term is used in Article 3(2) of the Prospectus Directive, (i)&nbsp;the shares acquired by it in the offering have not been acquired on behalf
of, nor have they been acquired with a view to their offer or resale to, persons in any Relevant Member State other than &#147;qualified investors&#148; (as defined in the Prospectus Directive), or in circumstances in which the prior consent of the
representative has been given to the offer or resale; or (ii)&nbsp;where shares have been acquired by it on behalf of persons in any Relevant Member State other than qualified investors, the offer of those shares to it is not treated under the
Prospectus Directive as having been made to such persons. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Prospectus does not constitute an issue prospectus pursuant to Article 652a or Article 1156 of the Swiss Code of Obligations
(&#147;CO&#148;) and the shares will not be listed on the SIX Swiss Exchange. Therefore, the Prospectus may not comply with the disclosure standards of the CO and/or the listing rules (including any prospectus schemes) of the SIX Swiss Exchange.
Accordingly, the shares may not be offered to the public in or from Switzerland, but only to a selected and limited circle of investors, which do not subscribe to the shares with a view to distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP, Palo Alto, California, will pass upon the validity of the common stock and warrants offered by this prospectus supplement. The
underwriters are being represented in connection with this offering by Proskauer Rose LLP, New York, New York. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_11">
</A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference from our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;13, 2017, have been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such
financial statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_12"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and accompanying prospectus is part of the registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement and accompanying
prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by
reference into this prospectus supplement and accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and
current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. You may also read and copy any document we file at the SEC&#146;s
Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further
information on the operation of the Public Reference Room. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus supplement and accompanying prospectus. Information in this prospectus supplement
supersedes information in the accompanying prospectus or incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement, while information that we file later with the SEC will automatically update and supersede
the information in this prospectus supplement and accompanying prospectus. We incorporate by reference into this prospectus supplement, the accompanying prospectus and the registration statement of which this prospectus supplement is a part the
information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-36365):</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;13, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended March&nbsp;31, 2017, filed with the SEC on May&nbsp;8, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2017, filed with the SEC on August&nbsp;8, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended September&nbsp;30, 2017, filed with the SEC on November&nbsp;7, 2017; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information specifically incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2016, from our Definitive Proxy Statement on
Schedule 14A, filed with the SEC on April&nbsp;26, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on January&nbsp;26, 2017, February&nbsp;6, 2017, March&nbsp;2, 2017, June&nbsp;19, 2017, February 15, 2018, and March 5, 2018;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form <FONT STYLE="white-space:nowrap">8-A</FONT> filed with the SEC on March&nbsp;19, 2014 (File
<FONT STYLE="white-space:nowrap">No.&nbsp;001-36365),</FONT> including any amendments or reports filed for the purposes of updating this description. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus supplement and accompanying prospectus and will become a part of this prospectus
supplement and accompanying prospectus from the date that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement and accompanying prospectus. Any
statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that
statements in the later filed document modify or replace such earlier statements. You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCYNEXIS, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 Hudson Street,
Suite 3610 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jersey City, NJ 07302-6548 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(201) <FONT STYLE="white-space:nowrap">884-5485</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn:&nbsp;Secretary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc540762_14"></A>ANNEX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PURSUANT TO THE TERMS OF SECTION 1 OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER
OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT SCYNEXIS, INC. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NUMBER OF SHARES
THAT MAY BE ACQUIRED PURSUANT TO THE EXERCISE OF THIS WARRANT </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCYNEXIS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrant to Purchase Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Series
[1][2] Warrant No.: 2018-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of Shares of Common
Stock: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date of Issuance: March
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 (&#147;<B>Issuance Date</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SCYNEXIS, Inc., a Delaware corporation
(the &#147;<B>Company</B>&#148;), certifies that, for good and valuable consideration, the receipt and sufficiency of which are acknowledged, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the
registered holder hereof or its permitted assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company, at the Exercise Price (as defined below) then in effect, upon exercise of this
Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;), at any time or times on or after the date hereof (the &#147;<B>Exercisability
Date</B>&#148;), but not after 5:30 p.m., New York Time, on the Expiration Date (as defined below),
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>(</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B>)</B> fully paid
and nonassessable shares of Common Stock (as defined below)&nbsp;(the &#147;<B>Warrant Shares</B>&#148;). Except as otherwise defined herein, capitalized terms in this Warrant shall have the meanings set forth in Section&nbsp;17. This Warrant is one
of a series of warrants (such warrants being both Series 1 warrants and Series 2 warrants) to purchase shares of Common Stock (collectively, the &#147;<B>Warrants</B>&#148;) issued on March 8, 2018 (the &#147;<B>Issuance Date</B>&#148;), pursuant to
the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-</FONT> 207705) (as amended) (the &#147;<B>Registration Statement</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>EXERCISE OF WARRANT</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Mechanics of Exercise</U>. Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in
Section&nbsp;1(f)), this Warrant may be exercised by the Holder on any day on or after the Exercisability Date, in whole or in part (but not as to fractional shares), by (i)&nbsp;delivery of a written notice, in the form attached hereto as
<U>Exhibit A</U> (the &#147;<B>Exercise Notice</B>&#148;), of the Holder&#146;s election to exercise this Warrant and (ii)&nbsp;if (A)&nbsp;a registration statement registering the issuance of the Warrant Shares under the Securities Act of 1933, as
amended (the &#147;<B>Securities Act</B>&#148;), is effective and available for the issuance of the Warrant Shares, or an exemption from registration under the Securities Act is available for the issuance of the Warrant Shares, payment to the
Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this Warrant is being exercised (the &#147;<B>Aggregate Exercise Price</B>&#148;) in cash or wire transfer of immediately available
funds (a &#147;<B>Cash Exercise</B>&#148;) or (B)&nbsp;the provisions of Section&nbsp;1(d) are available and this Warrant is exercised pursuant to a Cashless Exercise (as defined in Section&nbsp;1(d)). The Holder shall not be required to surrender
this Warrant in order to effect an exercise hereunder; provided, however, that in the event that this Warrant is exercised in full or for the remaining unexercised portion hereof, the Holder shall deliver this Warrant to the Company for cancellation
within a reasonable time after such exercise. On or before the first Trading Day following the date on which the Company has received the Exercise Notice (the date upon which the Company has received the Exercise Notice, the &#147;<B>Exercise
Date</B>&#148;), the Company shall transmit by facsimile or <FONT STYLE="white-space:nowrap">e-mail</FONT> transmission an acknowledgment of confirmation of receipt of the Exercise Notice to the Holder and the Company&#146;s transfer agent for the
Common Stock (the &#147;<B>Transfer Agent</B>&#148;). The Company shall deliver any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
objection to the Exercise Notice on or before the first Trading Day following the date on which the Company has received the Exercise Notice. On or before the second Trading Day following the
date on which the Company has received the Exercise Notice, so long as the Holder delivers the Aggregate Exercise Price (or notice of a Cashless Exercise) on or prior to the second (2nd) Trading Day following the date on which the Company has
received the Exercise Notice (the &#147;<B>Share Delivery Date</B>&#148;) (provided that if the Aggregate Exercise Price has not been delivered by such date, the Share Delivery Date shall be one (1)&nbsp;Trading Day after the Aggregate Exercise
Price (or notice of a Cashless Exercise) is delivered), the Company shall, (X)<U>&nbsp;provided</U> that the Transfer Agent is participating in The Depository Trust Company (&#147;<B>DTC</B>&#148;) Fast Automated Securities Transfer Program (the
&#147;<B>FAST Program</B>&#148;) and so long as the certificates therefor are not required to bear a legend regarding restriction on transferability, upon the request of the Holder, credit such aggregate number of shares of Common Stock to which the
Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with DTC through its Deposit Withdrawal At Custodian system, or (Y), if the Transfer Agent is not participating in the FAST Program or if the
certificates are required to bear a legend regarding restriction on transferability, issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company&#146;s share register in the
name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Notice, so long as the Holder delivers the Aggregate Exercise Price (or notice of a
Cashless Exercise) on or prior to the second (2nd) Trading Day following the date on which the Company has received the Exercise Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the certificates evidencing such Warrant Shares, as the case may be. If this
Warrant is submitted in connection with any exercise pursuant to this Section&nbsp;1(a) and the number of Warrant Shares represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise,
then the Company shall as soon as practicable and in no event later than three Trading Days after any such submission and at its own expense, issue a new Warrant (in accordance with Section&nbsp;7(e)) representing the right to purchase the number of
Warrant Shares purchasable immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant has been and/or is exercised. The Company shall pay any and all taxes and other expenses of the
Company (including overnight delivery charges) that may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant; <U>provided</U>, <U>however</U>, that the Company shall not be required to pay any tax
which may be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder or an affiliate thereof. The Holder shall be responsible for all other tax
liability that may arise as a result of transferring this Warrant or Warrant Shares upon exercise hereof to a third party. While this Warrant remains outstanding, the Company shall maintain a transfer agent that participates in the DTC Fast
Automated Securities Transfer Program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Exercise Price</U>. For purposes of this Warrant, &#147;<B>Exercise Price</B>&#148; means
$[$1.85][$2.00] per share of Common Stock, subject to adjustment as provided herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Failure to Timely Deliver Shares</U>. In
addition to any other rights available to a Holder, if the Company fails to deliver to the Holder the Warrant Shares by the Share Delivery Date, and if after such Share Delivery Date the Holder purchases (in an open market transaction or otherwise)
shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving from the Company (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;), then the Company shall,
within three Trading Days after the Holder&#146;s request and in the Holder&#146;s discretion, either (i)&nbsp;pay cash to the Holder in an amount equal to the Holder&#146;s total purchase price (including brokerage commissions, if any) for the
shares of Common Stock so purchased less the Exercise Price (the &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</B>&#148;), at which point the Company&#146;s obligation to deliver such certificate (and to issue such Common Stock)
shall terminate, or (ii)&nbsp;promptly honor its obligation to deliver to the Holder a certificate or certificates representing such Common Stock and pay cash to the Holder in an amount equal to the excess (if any) of the <FONT
STYLE="white-space:nowrap">Buy-In</FONT> Price over the product of (A)&nbsp;such number of shares of Common Stock, times (B)&nbsp;the per share closing price of the Company&#146;s Common Stock on the date of the event giving rise to the
Company&#146;s obligation to deliver such certificate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Cashless Exercise</U>. Notwithstanding anything contained herein to the contrary, if
a registration statement registering the issuance of the Warrant Shares under the Securities Act is not effective or available for the issuance of the Warrant Shares, the Holder may, in its sole discretion, exercise this Warrant in whole or in part
and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the &#147;Net Number&#148; of shares of Common Stock
determined according to the following formula (a &#147;<B>Cashless Exercise</B>&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>Net&nbsp;Number&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">(A&nbsp;x&nbsp;B)&nbsp;-&nbsp;(A&nbsp;x&nbsp;C)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">B</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>A&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the total number of shares with respect to which this Warrant is then being exercised.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>B&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the Weighted Average Price of the shares of Common Stock (as reported by Bloomberg) on the date immediately preceding the date of the Exercise Notice.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>C&nbsp;=</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby covenants and agrees that the Warrant Shares issued in a Cashless Exercise shall be deemed
to have been acquired by the Holder pursuant to Section&nbsp;3(a)(9) of the Securities Act. For purposes of Rule 144(d) promulgated under the Securities Act, as in effect on the date hereof, assuming the Holder is not an affiliate of the Company, it
is intended that the Warrant Shares issued in a Cashless Exercise shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the closing date of the offering pursuant to
which the Company was obligated to issue this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to
transmit to the Holder the Warrant Shares pursuant to Section 1(a) by the Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <U>Limitations on Exercises</U>. (1)&nbsp;The Company shall not effect the exercise of this Warrant, and the Holder shall not have the
right to exercise this Warrant, to the extent that after giving effect to such exercise, such Holder (together with such Holder&#146;s affiliates and any other Persons acting as a group together) would beneficially own in excess of 4.99% (the
&#147;<B>Maximum Percentage</B>&#148;) of the shares of Common Stock outstanding immediately after giving effect to such exercise. For purposes of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such
Person and its affiliates shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would be
issuable upon (i)&nbsp;exercise of the remaining, unexercised portion of this Warrant beneficially owned by such Person and its affiliates and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the
Company beneficially owned by such Person and its affiliates (including, without limitation, any convertible notes or convertible preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained
herein. Except as set forth in the preceding sentence, for purposes of this paragraph, beneficial ownership shall be calculated in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange
Act</B>&#148;), it being acknowledged that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the Exchange Act, and the Holder is solely responsible for any schedules required to be filed
in accordance therewith. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (1)&nbsp;the Company&#146;s most recent
Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public filing with the Securities and Exchange Commission, as the case
may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. For any reason at any time,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon the written or oral request of the Holder, where such request indicates that it is being made pursuant to this Warrant, the Company shall within two Trading Days confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
the Warrants, by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to the Company, the Holder may increase or decrease the Maximum Percentage to any other
percentage not in excess of 14.99% specified in such notice; <U>provided</U>, that (i)&nbsp;any such increase will not be effective until the 61st day after such notice is delivered to the Company and (ii)&nbsp;any such increase or decrease will
apply only to the Holder and not to any other holder of Warrants. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section&nbsp;1(f) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended beneficial ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share that the Holder would otherwise be entitled to purchase upon such exercise, the Company shall pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>ADJUSTMENT OF EXERCISE PRICE AND NUMBER OF WARRANT SHARES</U>. The Exercise Price and the number of Warrant Shares
shall be adjusted from time to time as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Adjustment upon Subdivision or Combination of Shares of Common Stock</U>. If the
Company at any time on or after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in
effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse stock split
or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares will
be proportionately decreased. Any adjustment under this Section&nbsp;2(a) shall become effective at the close of business on the date the subdivision or combination becomes effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Other Events</U>. If any event occurs of the type contemplated by the provisions of Section&nbsp;2(a) but not expressly provided for by
such provisions (including, without limitation, the granting of stock appreciation rights, phantom stock rights or other rights with equity features to the holders of the Company&#146;s equity securities), then the Company&#146;s Board of Directors
will make an appropriate adjustment in the Exercise Price and the number of Warrant Shares so as to protect the rights of the Holder; <U>provided</U>, that no such adjustment pursuant to this Section&nbsp;2(b) will increase the Exercise Price or
decrease the number of Warrant Shares as otherwise determined pursuant to this Section&nbsp;2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) Notwithstanding anything to the
contrary in this Warrant, in no event shall the Exercise Price be reduced below the par value of the Company&#146;s Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>RIGHTS UPON DISTRIBUTION OF ASSETS</U>. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&#147;<B>Distribution</B>&#148;), at any time after the issuance of this Warrant, then, in each such case: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) any Exercise Price in
effect immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution shall be reduced, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective as of the close of business on such record date, to a price determined by multiplying such Exercise Price by a fraction of which (i)&nbsp;the numerator shall be the Weighted Average
Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined in good faith by the Company&#146;s Board of Directors) applicable to one share of Common Stock, and
(ii)&nbsp;the denominator shall be the Weighted Average Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding paragraph
(a); <U>provided</U>, that in the event that the Distribution is of shares of Common Stock or common stock of a company whose common shares are traded on a national securities exchange or a national automated quotation system (&#147;<B>Other Shares
of Common Stock</B>&#148;), then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of Warrant Shares, the terms of which shall be identical to those of this Warrant, except that
such warrant shall be exercisable into the number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution had the Holder exercised this Warrant immediately prior to such record date and with
an aggregate exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the terms of the immediately preceding paragraph (a)&nbsp;and the number of Warrant
Shares calculated in accordance with the first part of this paragraph (b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>PURCHASE RIGHTS. FUNDAMENTAL TRANSACTIONS</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Purchase Rights</U>. In addition to any adjustments pursuant to Section&nbsp;2 above, if at any time prior to the Expiration Date the
Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#147;<B>Purchase Rights</B>&#148;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete
exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as
of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would
result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage, at which time the Holder shall be granted such
right to the same extent as if there had been no such limitation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(b) <U>Fundamental Transactions</U>. Upon the occurrence of any
Fundamental Transaction, the Successor Entity to succeed, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#147;Company&#148; shall refer instead to the
Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein. Upon
consummation of the Fundamental Transaction, the Successor Entity shall deliver to the Holder confirmation that there shall be issued upon exercise of this Warrant at any time after the consummation of the Fundamental Transaction, in lieu of the
shares of the Common Stock (or other securities, cash, assets or other property purchasable upon the exercise of the Warrant prior to such Fundamental Transaction), such shares of stock, securities, cash, assets or any other property whatsoever
(including warrants or other purchase or subscription rights), if any, that the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had this Warrant been exercised immediately prior to such Fundamental
Transaction, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as adjusted in accordance with the provisions of this Warrant. In addition to and not in substitution for any other rights hereunder, prior to the consummation of any Fundamental Transaction
pursuant to which holders of shares of Common Stock are entitled to receive securities or other assets with respect to or in exchange for shares of Common Stock (a <B>&#147;Corporate Event&#148;</B>), the Company shall make appropriate provision to
ensure that the Holder will thereafter have the right to receive upon an exercise of this Warrant within 90 days after the consummation of the Fundamental Transaction but, in any event, prior to the Expiration Date, in lieu of the shares of the
Common Stock (or other securities, cash, assets or other property) purchasable upon the exercise of the Warrant prior to such Fundamental Transaction, such shares of stock, securities, cash, assets or any other property whatsoever (including
warrants or other purchase or subscription rights) which the Holder would have been entitled to receive upon the happening of such Fundamental Transaction had the Warrant been exercised immediately prior to such Fundamental Transaction and shall be
applied without regard to any limitations on the exercise of this Warrant. Provision made pursuant to the preceding sentence shall be in a form and substance reasonably satisfactory to the Required Holders. The provisions of this
Section&nbsp;4(b)(ii) shall apply similarly and equally to successive Fundamental Transactions and Corporate Events and shall be applied without regard to any limitations on the exercise of this Warrant. Notwithstanding the foregoing, in the event
of a Fundamental Transaction, at the request of the Holder delivered before the consummation of such Fundamental Transaction, the Company (or the Successor Entity) shall purchase this Warrant from the Holder by paying to the Holder, within five
(5)&nbsp;Business Days after such request (or, if later, on the date of consummation of the Fundamental Transaction) cash in an amount equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the
consummation of such Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>RESERVATION OF WARRANT SHARES</U>. The Company covenants that it will at all times
reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of
shares of Common Stock which are then issuable and deliverable upon the exercise of this entire Warrant, free from preemptive or any other contingent purchase rights of Persons other than the Holder (taking into account the adjustments and
restrictions in Section&nbsp;2). Such reservation shall comply with the provisions of Section&nbsp;1. The Company covenants that all shares of Common Stock so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise
Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and nonassessable. The Company will take all such actions as may be necessary to assure that such shares of Common Stock may be issued as provided
herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>WARRANT HOLDER NOT DEEMED A STOCKHOLDER</U>. Except as otherwise specifically provided herein, the Holder, solely in such Person&#146;s
capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder,
solely in such Person&#146;s capacity as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then
entitled to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a
stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>REGISTRATION AND
REISSUANCE OF WARRANTS</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration of Warrant</U>. The Company shall register this Warrant, upon the records to be
maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. The Company shall also register any transfer,
exchange, reissuance or cancellation of any portion of this Warrant in the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <U>Transfer of Warrant</U>. This Warrant
may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be required by applicable securities laws. Subject to applicable securities laws, if this Warrant is to be transferred, the Holder
shall surrender this Warrant to the Company together with all applicable transfer taxes, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section&nbsp;7(e)), registered as the
Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance
with Section&nbsp;7(e)) to the Holder representing the right to purchase the number of Warrant Shares not being transferred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <U>Lost,
Stolen or Mutilated Warrant</U>. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification
undertaking by the Holder to the Company in customary form or the provision of reasonable security by the Holder to the Company and, in the case of mutilation, upon surrender and cancellation of this Warrant, the Company shall execute and deliver to
the Holder a new Warrant (in accordance with Section&nbsp;7(e)) representing the right to purchase the Warrant Shares then underlying this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <U>Exchangeable for Multiple Warrants</U>. This Warrant is exchangeable, upon the surrender hereof by the Holder at the principal office
of the Company together with all applicable transfer taxes, for a new Warrant or Warrants (in accordance with Section&nbsp;7(e)) representing in the aggregate the right to purchase the number of Warrant Shares then underlying this Warrant, and each
such new Warrant will represent the right to purchase such portion of such Warrant Shares as is designated by the Holder at the time of such surrender; <U>provided</U>, <U>however</U>, that the Company shall not be required to issue Warrants for
fractional shares of Common Stock hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <U>Issuance of New Warrants</U>. Whenever the Company is required to issue a new Warrant
pursuant to the terms of this Warrant, such new Warrant shall (i)&nbsp;be of like tenor with this Warrant, (ii)&nbsp;represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or
in the case of a new Warrant being issued pursuant to Section&nbsp;7(b) or Section&nbsp;7(c), the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in
connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii)&nbsp;have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date and (iv)&nbsp;have the
same rights and conditions as this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>NOTICES</U>. Whenever notice is required to be given under this Warrant, unless
otherwise provided herein, such notice shall be given in accordance with the information set forth in the Warrant Register. The Company shall provide the Holder with prompt written notice of all actions taken pursuant to this Warrant, including, in
reasonable detail, a description of such action and the reason or reasons therefore. Without limiting the generality of the foregoing, the Company will give written notice to the Holder (i)&nbsp;immediately upon any adjustment of the Exercise Price,
setting forth in reasonable detail, and certifying, the calculation of such adjustment and (ii)&nbsp;at least 20 days prior to the date on which the Company closes its books or takes a record (A)&nbsp;with respect to any dividend or distribution
upon the shares of Common Stock, (B)&nbsp;with respect to any grants, issuances or sales of any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock or (C)&nbsp;for determining rights to vote with respect to any Fundamental Transactions, dissolution or liquidation; <U>provided</U>, that in each case, such information shall be made known to the public prior to or in conjunction
with such notice being provided to the Holder. To the extent that any notice provided in the Warrant constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>NONCIRCUMVENTION</U>. The Company hereby covenants and agrees that the Company will
not, by amendment of its Amended and Restated Articles of Incorporation, Amended and Restated Bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities or any
other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required to protect the
rights of the Holder. Without limiting the generality of the foregoing, the Company (i)&nbsp;shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii)&nbsp;shall use all reasonable efforts to take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant and
(iii)&nbsp;shall, so long as any of the Warrants are outstanding, take all action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock, solely for the purpose of effecting the exercise of the Warrants,
the number of shares of Common Stock as shall from time to time be necessary to effect the exercise of the Warrants then outstanding (without regard to any limitations on exercise). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>AMENDMENT AND WAIVER</U>. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Required Holders; <U>provided</U>, that no such action may increase the exercise price of any
Warrant or decrease the number of shares or class of stock obtainable upon exercise of any Warrant without the written consent of the Holder. No such amendment shall be effective to the extent that it applies to less than all of the holders of the
Warrants then outstanding. No consideration shall be offered or paid to any Person to amend or consent to a waiver or modification of any provision of any Warrants unless the same consideration (other than the reimbursement of legal fees) also is
offered to all holders of the Warrants, including the Holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>GOVERNING LAW</U>. This Warrant shall be governed by and construed
and enforced in accordance with, and all questions concerning the construction, validity, interpretation and performance of this Warrant shall be governed by, the internal laws of the State of New York, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>CONSTRUCTION; HEADINGS</U>. This Warrant shall be deemed to be jointly drafted by the Company and all the Investors and shall not be
construed against any person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>DISPUTE RESOLUTION</U>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the
Warrant Shares, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two Trading Days of receipt of the Exercise Notice giving rise to such dispute, as the case may be, to the Holder. If the Holder and
the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within five Trading Days of such disputed determination or arithmetic calculation being submitted to the Holder, then the Company
shall, within two Trading Days submit via facsimile (a)&nbsp;the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the Company and approved by the Holder or (b)&nbsp;the disputed arithmetic
calculation of the Warrant Shares to the Company&#146;s independent, outside accountant. The Company shall cause the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company and the
Holder of the results no later than 10 Trading Days from the time it receives the disputed determinations or calculations. Such investment bank&#146;s or accountant&#146;s determination or calculation, as the case may be, shall be binding upon all
parties absent demonstrable error. The expenses of the investment bank and accountant will be borne by the Company unless the investment bank or accountant determines that the determination of the Exercise Price or the arithmetic calculation of the
Warrant Shares by the Holder was incorrect, in which case the expenses of the investment bank and accountant will be borne by the Holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U>. The remedies
provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the
right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its obligations hereunder may cause irreparable harm to the Holder and that the
remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to seek an
injunction restraining any breach. Notwithstanding the foregoing or anything else herein to the contrary, other than as expressly provided in Section&nbsp;1(c) hereof, if the Company is for any reason unable to issue and deliver Warrant Shares upon
exercise of this Warrant as required pursuant to the terms hereof, the Company shall have no obligation to pay to the Holder any cash or other consideration or otherwise &#147;net cash settle&#148; this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>LIMITATION ON LIABILITY</U>. No provisions hereof, in the absence of affirmative action by the Holder to purchase Warrant Shares
hereunder, shall give rise to any liability of the Holder to pay the Exercise Price or as a shareholder of the Company (whether such liability is asserted by the Company or creditors of the Company). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>SUCCESSORS AND ASSIGNS</U>. This Warrant shall bind and inure to the benefit of and be enforceable by the Company and the Holder and
their respective permitted successors and assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17. <U>CERTAIN DEFINITIONS</U>. For purposes of this Warrant, the following terms
shall have the following meanings: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&#147;<B>Black Scholes Value</B>&#148; means the value of this Warrant based on the
Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg determined as of the day immediately following the first public announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is
not publicly announced, the date the Fundamental Transaction is consummated, for pricing purposes and reflecting (i)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as
of such date of request, (ii)&nbsp;an expected Volatility obtained from the HVT function on Bloomberg as of the day immediately following the public announcement of the applicable Fundamental Transaction, or, if the Fundamental Transaction is not
publicly announced, the date the Fundamental Transaction is consummated, (iii)&nbsp;the underlying price per share used in such calculation shall be the highest Weighted Average Price during the five (5)&nbsp;Trading Days prior to the closing of the
Fundamental Transaction, (iv)&nbsp;a zero cost of borrow and (v)&nbsp;a 360 day annualization factor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Bloomberg</B>&#148;
means Bloomberg LP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Common Stock</B>&#148; means (i)&nbsp;the Company&#146;s shares of Common Stock, $0.001 par value per
share, and (ii)&nbsp;any share capital into which such Common Stock shall have been changed or any share capital resulting from a reclassification of such Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Convertible Securities</B>&#148; means any stock or securities (other than Options) directly or indirectly convertible into or
exercisable or exchangeable for shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Eligible Market</B>&#148; means The New York Stock Exchange, Inc.,
the NYSE American or The Nasdaq Stock Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Expiration Date</B>&#148; means the [Series 1 warrant, fifty three (53) week;
Series 2 warrant, five (5) year] anniversary of the Issuance Date or, if such date falls on a day other than a Trading Day or on which trading does not take place on the Principal Market, or, if the Principal Market is not the principal trading
market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded (a &#147;<B>Holiday</B>&#148;), the next date that is not a Holiday. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&#147;<B>Fundamental Transaction</B>&#148; means that the Company shall, directly
or indirectly, in one or more related transactions, (i)&nbsp;consolidate or merge with or into another Person, (ii)&nbsp;sell, assign, transfer, convey or otherwise dispose of all or substantially all of the properties or assets of the Company to
another Person, (iii)&nbsp;allow another Person to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of either the outstanding shares of Common Stock (not including any shares of Common Stock held by the
Person or Persons making or party to, or associated or affiliated with the Persons making or party to, such purchase, tender or exchange offer), (iv) consummate a stock purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding shares of Common Stock (not including any shares
of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination), (v) reorganize, recapitalize or
reclassify its Common Stock or (vi)&nbsp;any &#147;person&#148; or &#147;group&#148; (as these terms are used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall become the &#147;beneficial owner&#148; (as defined in Rule <FONT
STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) &#147;<B>Options</B>&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible
Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Parent Entity</B>&#148; of a Person means an entity that, directly or indirectly, controls the applicable Person
and whose common stock or equivalent equity security is quoted or listed on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest public market capitalization as of the date of
consummation of the Fundamental Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Person</B>&#148; means an individual, a limited liability company, a
partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Principal Market</B>&#148; means The Nasdaq Global Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Required Holders</B>&#148; means the holders of the Warrants representing at least a majority of shares of Common Stock
underlying the Warrants then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Successor Entity</B>&#148; means the Person (or, if so elected by the Required
Holders, the Parent Entity) formed by, resulting from or surviving any Fundamental Transaction or the Person (or, if so elected by the Required Holders, the Parent Entity) with which such Fundamental Transaction shall have been entered into. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(n) &#147;<B>Trading Day</B>&#148; means any day on which the Common Stock is traded on the Principal Market, or, if the Principal Market is
not the principal trading market for the Common Stock, then on the principal securities exchange or securities market on which the Common Stock is then traded; <U>provided</U> that &#147;Trading Day&#148; shall not include any day on which the
Common Stock is scheduled to trade on such exchange or market for less than 4.5&nbsp;hours or any day that the Common Stock is suspended from trading during the final hour of trading on such exchange or market (or if such exchange or market does not
designate in advance the closing time of trading on such exchange or market, then during the hour ending at 4:00:00 p.m., New York Time). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(o) &#147;<B>Volatility</B>&#148; means the arithmetic mean of the historical Volatility for the 10, 30 and 50 Trading Day periods ending on
the next succeeding Trading Day following the date of such first public announcement, obtained from the HVT or similar function on Bloomberg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(p) &#147;<B>Weighted Average Price</B>&#148; means, for any security as of any date, the dollar volume-weighted average price for such
security on the Principal Market, or, if the Principal Market is not the principal trading market for the Common Stock, then on the principal securities exchange on which the Common Stock is then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
traded, during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg through its &#147;Volume at Price&#148; function
or, if the foregoing does not apply, the dollar volume-weighted average price of such security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such
security during the period beginning at 9:30:01 a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if no dollar volume-weighted average price is reported for such security by Bloomberg for such
hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security as reported in the &#147;pink sheets&#148; by OTC Markets Inc. If the Weighted Average Price cannot be calculated for
such security on such date on any of the foregoing bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company and the Required Holders. If the Company and the Required Holders
are unable to agree upon the fair market value of such security, then such dispute shall be resolved pursuant to Section&nbsp;13 with the term &#147;Weighted Average Price&#148; being substituted for the term &#147;Exercise Price.&#148; All such
determinations shall be appropriately adjusted for any share dividend, share split or other similar transaction during such period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF,</B> the Company has caused this Warrant to Purchase Common Stock to
be duly executed as of the Issuance Date set out above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>SCYNEXIS, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXERCISE NOTICE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE
EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCYNEXIS, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned holder
hereby exercises the right to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of the shares of Common Stock (&#147;<B>Warrant Shares</B>&#148;) of SCYNEXIS, Inc., a Delaware corporation (the
&#147;<B>Company</B>&#148;), evidenced by the attached Warrant to Purchase Common Stock (the &#147;<B>Warrant</B>&#148;). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Exercise Price</U>. The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; Cash Exercise under Section&nbsp;1(a). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; Cashless Exercise under Section&nbsp;1(d) (provided the conditions therein are satisfied). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Cash Exercise</U>. If the Holder has elected a Cash Exercise, the Holder shall pay the sum of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to the Company in accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Delivery of Warrant
Shares</U>. The Company shall deliver to the holder &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warrant Shares in accordance with the terms of the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Representations and Warranties</U>. By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that
in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted
to be owned under Section&nbsp;1(f) of this Warrant to which this notice relates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Name of Registered Holder </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title :</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g540762g42k37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may offer and sell up to an aggregate amount of $150,000,000 any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stock upon conversion of debt
securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one
or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should
carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents incorporated by reference, before buying any of the securities being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Market under the trading symbol &#147;SCYX.&#148; On November 16, 2015, the last reported sale
price of our common stock was $7.00 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The NASDAQ Global Market or other securities exchange of the securities covered by the
applicable prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the
heading &#147;<A HREF="#toc202358_3">Risk Factors</A>&#148; contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the
other documents that are incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of
securities unless accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold directly by us to investors, through agents
designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. If any agents or underwriters are involved in
the sale of any securities with respect to which this prospectus is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement.
The price to the public of such securities and the net proceeds that we expect to receive from such sale will also be set forth in a prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is November 16, 2015. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc202358_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form&nbsp;S-3 that we filed with the Securities and Exchange Commission, or SEC,
utilizing a &#147;shelf&#148; registration process. Under this shelf registration statement, we may, from time to time, offer and sell, either individually or in combination, in one or more offerings, up to a total dollar amount of $150,000,000 any
of the securities described in this prospectus. This prospectus provides you with a general description of the securities we may offer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about
the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that
we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to read carefully this prospectus,
any applicable prospectus supplement and any free writing prospectuses we have authorized for use in connection with a specific offering, together with the information incorporated herein by reference as described under the heading
&#147;Incorporation of Certain Information by Reference,&#148; before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may
not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the
information contained in, or incorporated by reference into, this prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific
offering. We have not authorized anyone to provide you with different or additional information. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement or any
related free writing prospectus is accurate only as of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of
delivery of this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as
exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#147;Where You Can Find More Information.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we
are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various
factors, including those discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the
information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable
prospectus supplement or any related free writing prospectus are the property of their respective owners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks
of investing in our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>References in this prospectus to &#147;SCYNEXIS&#148;, &#147;the Company,&#148; &#147;we&#148;, &#147;us&#148; and &#147;our&#148;
refer to SCYNEXIS,&nbsp;Inc., a Delaware corporation, and its consolidated subsidiaries, if any, unless otherwise specified. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCYNEXIS, Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet
therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective <I>in
vitro</I> and <I>in vivo</I> in animal studies against a broad range of <I>Candida</I> and <I>Aspergillus</I> species, including drug resistant strains. These important pathogens account for approximately 85% of invasive fungal infections in the
United States and Europe. <FONT STYLE="white-space:nowrap">SCY-078</FONT> was shown to be sufficiently safe and well-tolerated in multiple Phase 1 studies to support progression to Phase 2 studies. We are currently conducting a multicenter Phase 2
study with primary endpoints of safety, tolerability, and pharmacokinetics of the oral formulation of SCY-078 as step-down treatment in patients initially treated with echinocandin therapy for invasive <I>Candida</I> infections. Enrollment into the
study continues but has been slower than anticipated.&nbsp;New investigational sites have been opened in the US and we are opening additional investigational sites in Latin America and Europe. Investigational sites are currently operating under the
latest protocol amendment, which was designed to facilitate enrollment, and we continue to consider whether further protocol amendments may be appropriate. These measures are expected to increase enrollment into the study. In addition, as we collect
data on the enrolled patients, we will continue to assess the actual number of patients required to achieve the study objectives. We expect to complete the study and to report top line data in the first half of 2016. We also recently initiated
enrollment in the first Phase 1 study of an IV formulation of SCY-078. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also planning to investigate the potential clinical utility
of SCY-078 in other areas of unmet medical need such as genital infections in women caused by <I>Candida</I> spp. (vulvovaginal candidiasis, or VVC). VVC is a highly prevalent condition with limited therapeutic options for infections caused by
azole-resistant <I>Candida</I> spp. We are planning to commence a Phase 2 study evaluating the safety and efficacy of orally administered SCY-078 in this indication during the fourth quarter of 2015. The data from this study is also expected to
provide a confirmation of the potential therapeutic effect of orally administered SCY-078 in a clinical condition caused by <I>Candida</I> spp. and, along with the other clinical and nonclinical data from ongoing and planned activities, will
contribute to the package of information that will support subsequent phases of development of SCY-078. Prior to our strategic focus on the development of SCY-078 for the treatment of invasive fungal infections, our drug discovery initiatives
produced clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, which we have licensed to partners for continued development and commercialization. In addition to pursuing the development of SCY-078, we
have additional compounds similar to SCY-078 and related expertise that we may use to expand our antifungal portfolio. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were originally incorporated in Delaware in November 1999 as ScyRex, Inc. We subsequently changed our name to SCYNEXIS Chemistry&nbsp;&amp;
Automation, Inc. in April 2000 and to SCYNEXIS, Inc. in June 2002. Our principal executive offices are located at 101 Hudson Street, Suite 3610, Jersey City, NJ 07302-6548, and our telephone number is (201) 884-5485. Our website address is
<I>www.scynexis.com</I>. The information contained on our website is not incorporated by reference into this prospectus, and you should not consider any information contained on, or that can be accessed through, our website as part of this
prospectus or in deciding whether to purchase our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risk Factors Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this
prospectus summary. You should read these risks, and the risks incorporated by reference into this prospectus, before you invest in our common stock. In particular, our risks include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we have never been profitable, we have no products approved for commercial sale, and to date we have not generated any revenue from product sales; as a result, our ability to curtail our losses and reach profitability
is unproven, and we may never achieve or sustain profitability; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we expect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may continue to require substantial additional capital, and if we are unable to raise capital when needed we would be forced to delay, reduce or eliminate our product development programs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">historically we have devoted a majority of our resources and efforts to providing research and development services to other companies and we have derived substantially all of our revenue from providing these services;
however, in July 2015, we completed the divestment of our contract research and development services business and have shifted our focus to developing our own drug candidate SCY-078; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we expect the divestiture of our contract research and development services business to result in a decrease of our reported revenues in 2015 and in an increase in our net loss in 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we cannot be certain that SCY-078 will receive regulatory approval, and without regulatory approval we will not be able to market SCY-078. Regulatory approval is a lengthy, expensive and uncertain process;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">although the oral form of SCY-078 has been granted Qualified Infectious Disease Product, or QIDP, designation, this does not guarantee that the length of the U.S. Food and Drug Administration, or FDA, review process
will be significantly shorter than otherwise, or that SCY-078 will ultimately be approved by the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in the enrollment, including delays in the implementation of any amendments to the Phase 2 study&#146;s protocol enrollment criteria, or delays in the completion of or the termination of our Phase 2 clinical
trial (or future clinical trials) could result in increased costs to us and could delay or limit our ability to obtain regulatory approval for <FONT STYLE="white-space:nowrap">SCY-078</FONT> or any future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical failure can occur at any stage of clinical development. Because the results of earlier clinical trials are not necessarily predictive of future results, any product candidate we or our current or potential
future partners advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval; </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we have limited experience in conducting clinical trials and has never submitted an NDA before, and we may be unable to do so for SCY-078 or any future product candidate we may seek to develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if SCY-078 or any other future product candidates for which we receive regulatory approval do not achieve broad market acceptance, the revenue that is generated from their sales will be limited; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a significant use of antifungal drugs consists of treatment due to the presence of symptoms before diagnosis of the invasive fungal infections, and if recently approved diagnostic tools, or additional tools currently
under development, for the quick diagnosis of invasive fungal infections are broadly used in the marketplace, the number of treatments using antifungal drugs may decrease significantly, decreasing the potential market for SCY-078; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if resistance to SCY-078 develops quickly or cross resistance with echinocandins becomes more common, our business will be harmed. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, up to a total dollar amount of $150,000,000, from time to time under this
prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of any offering. We may also offer common stock, preferred stock and/or
debt securities upon the exercise of warrants. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement
that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">designation or classification; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">aggregate principal amount or aggregate offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maturity date, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">original issue discount, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">rates and times of payment of interest or dividends, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption, conversion, exercise, exchange or sinking fund terms, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon
conversion or exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ranking; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictive covenants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting or other rights, if any; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">material or special U.S. federal income tax considerations, if any. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus
supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no
prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors or to or through agents, underwriters or
dealers. We, and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will include in the applicable prospectus
supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the names of those agents or underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">applicable fees, discounts and commissions to be paid to them; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">details regarding over-allotment options, if any; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the net proceeds to us. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY&nbsp;NOT BE USED TO CONSUMMATE A SALE OF SECURITIES UNLESS IT
IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock</I>. We may issue shares of our common stock from time to time. The holders
of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock
are entitled to receive ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets
remaining after payment of liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no
redemption or sinking fund provisions applicable to our common stock. In this prospectus, we have summarized certain general features of our common stock under &#147;Description of Capital Stock &#151; Common Stock.&#148;&nbsp;We urge you, however,
to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock. </I>We may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will
determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or
repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities.
Conversion may be mandatory or at the holders&#146; option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of
preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in
the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate
of designation that contains the terms of the series of preferred stock we are offering. In this prospectus, we have summarized certain general features of the preferred stock under &#147;Description of Capital Stock &#151; Preferred Stock.&#148; We
urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of
designation that contains the terms of the applicable series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Debt Securities. </I>We may issue debt securities
from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt
securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may be mandatory or at the holders&#146; option and
would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any debt securities issued under this prospectus will be issued under one or more documents
called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under &#147;Description of Debt
Securities.&#148; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as well as the complete
indentures that contain the terms of the debt securities. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the
terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants. </I>We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may
issue warrants independently or in combination with common stock, preferred stock and/or debt securities. In this prospectus, we have summarized certain general features of the warrants under &#147;Description of Warrants.&#148; We urge you,
however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as any warrant agreements and warrant
certificates that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this
prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant
certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant
agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in
any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any,
for working capital and general corporate purposes, including research and development expenses and capital expenditures. See &#147;Use of Proceeds&#148; in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The NASDAQ Global Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The NASDAQ Global Market under the symbol &#147;SCYX.&#148; The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on The NASDAQ Global Market or any other securities
market or other exchange of the securities covered by the applicable prospectus supplement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and discussed under the section entitled &#147;Risk Factors&#148; contained
in our most recent Annual Report on Form 10-K and in our most recent Quarterly Report on Form 10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their
entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering. The risks described in these documents are not the
only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial
performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of
operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &#147;Special Note
Regarding Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are incorporated by reference contain &#147;forward-looking statements&#148;
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our
future operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop SCY-078, including an IV formulation of SCY-078; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully implement and complete enrollment in our Phase 2 study with the oral formulation of SCY-078; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the benefits we will obtain from the oral form SCY-078 having been designated as a QIDP and the expectation that the IV form will also be designated as a QIDP; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain FDA approval of SCY-078; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the devotion of our resources; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expected uses of the net proceeds to us from any specific offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expected costs of studies and when they will begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to scale up manufacturing to commercial scale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reliance on third parties to conduct our clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reliance on third-party contract manufacturers to manufacture and supply commercial supplies of SCY-078 for us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the marketing of SCY-078 should we receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability to obtain additional financing; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our financial performance; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments and projections relating to our competitors or our industry. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you
can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148;
&#147;estimate,&#148; &#147;project,&#148; &#147;predict,&#148; &#147;potential&#148; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on
assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks under the heading &#147;Risk Factors&#148;
contained in the applicable prospectus supplement, in any free writing prospectuses we may authorize for use in connection with a specific offering, and in our most recent annual report on Form 10-K and in our most recent quarterly report on Form
10-Q, as well as any amendments thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as
of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not
assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, any applicable prospectus supplement, together with the documents we have filed
with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what
we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_5">
</A>USE OF PROCEEDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have
authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital and general corporate purposes, including research and
development expenses and capital expenditures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amounts and timing of our use of the net proceeds from this offering will depend on a
number of factors, such as the timing and progress of our research and development efforts, the timing and progress of any partnering and commercialization efforts, technological advances and the competitive environment for our products. As of the
date of this prospectus, we cannot specify with certainty all of the particular uses for the net proceeds to us from the sale of the securities offered by us hereunder. Accordingly, our management will have broad discretion in the timing and
application of these proceeds. Pending application of the net proceeds as described above, we intend to temporarily invest the proceeds in short-term, interest-bearing instruments. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock does not purport to be complete and is subject in all respects to applicable Delaware law and
to the provisions of our amended and restated certificate of incorporation, and our amended and restated bylaws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides for common stock and authorized shares of undesignated preferred stock, the
rights, preferences and privileges of which may be designated from time to time by our board of directors. As of October&nbsp;30, 2015, our authorized capital stock consists of 130,000,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares, all with a par value of $0.001 per share, of which 125,000,000 shares are designated as common stock and 5,000,000 shares are designated as preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each holder of our common stock is entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders,
except as otherwise expressly provided in our amended and restated certificate of incorporation or required by applicable law. Cumulative voting for the election of directors is not provided for in our amended and restated certificate of
incorporation, which means that the holders of a majority of our shares of common stock can elect all of the directors then standing for election. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Dividends and Distributions. </I>Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the
holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available at the times and in the amounts that our board of directors may determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Liquidation Rights. </I>Upon our liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders
would be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time after payment of liquidation preferences, if any, on any outstanding shares of preferred stock and payment of other
claims of creditors. The rights, preferences, and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of holders of shares of any series of preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preemptive or Similar Rights</I>. Our common stock is not entitled to preemptive rights and is not subject to conversion,
redemption or sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 5,000,000 shares of preferred stock in
one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any of its qualifications, limitations or restrictions.
Our board of directors can also increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that series then outstanding, without any further vote or action by the our stockholders. Our board of
directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in
connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring, discouraging or preventing a change in control or other corporate action and may adversely affect the market price
of our common stock and the voting and other rights of the holders of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers,
preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to
the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that contains the terms of the series of preferred stock we are
offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares we are offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the liquidation preference per share; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dividend rate, period and payment date and method of calculation for dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the procedures for any auction and remarketing, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for a sinking fund, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange or market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voting rights of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preemptive rights, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on transfer, sale or other assignment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interests in the preferred stock will be represented by depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of material United States federal income tax considerations applicable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our
affairs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of October 30,
2015, we had outstanding warrants to purchase an aggregate of 14,033 shares of our common stock with an exercise price of $45.61 per share. Each of these warrants has a net exercise provision under which the holder, in lieu of payment of the
exercise price in cash, can surrender the warrant and receive a net number of shares of common stock based on the fair market value of such stock at the time of exercise of the warrant after deduction of the aggregate exercise price. Unless earlier
exercised, these warrants will expire on the five year anniversary of our initial public offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are party to an investor rights agreement which provides certain holders of shares of our common stock with certain registration rights, as
set forth below. The registration of shares of our common stock pursuant to the exercise of registration rights described below would enable the holders to sell these shares without restriction under the Securities Act of 1933, as amended, or the
Securities Act, when the applicable registration statement is declared effective. We will pay the registration expenses, other than underwriting discounts and commissions, of the shares registered pursuant to the demand, piggyback and Form S-3
registrations described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, in an underwritten offering, the underwriter has the right, subject to specified
conditions, to limit the number of shares such holders may include. The demand, piggyback and Form S-3 registration rights described below will expire the later of (1)&nbsp;three years after the effective date of the registration statement in
connection with our initial public offering, or (2)&nbsp;with respect to each stockholder, at such time as the (A)&nbsp;our capital stock is publicly traded and (B)&nbsp;such stockholder holds less than one percent (1%)&nbsp;of the our common stock
outstanding and is entitled to sell all of its shares pursuant to Rule 144 of the Securities Act during any 90&nbsp;day period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Demand
Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain demand registration rights. At any time
before the expiration of the registration rights, the holders of forty percent (40%)&nbsp;of these shares may request that we file a registration statement having an aggregate offering price to the public of not less than $5.0 million to register
all or a portion of their shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that we propose in the future to register any of our securities under the Securities Act either for our own account or for the
account of other security holders, certain holders of our common stock will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in the registration, subject to certain marketing and other
limitations. As a result, whenever we propose to file a registration statement under the Securities Act including a registration statement on Form S-3 as discussed below, other than with respect to a demand registration or a registration statement
on Forms S-4 or S-8, the holders of these shares are entitled to notice of the registration and have the right, subject to limitations that the underwriters may impose on the number of shares included in the registration, to include their shares in
the registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Form S-3 Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain Form S-3 registration rights. These holders may make a request that we
register their shares on Form S-3 if we are qualified to file a registration statement on Form S-3. The request for registration on Form S-3 must cover securities the aggregate offering price of which, before payment of underwriting discounts and
commissions, is at least $1,000,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Provisions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Certificate of Incorporation and Bylaws </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the voting power of our shares of common
stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide that all stockholder actions must be effected at a duly called meeting of stockholders and
not by consent in writing. A special meeting of stockholders may be called only by a majority of our whole board of directors, the chair of our board of directors, or our chief executive officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation further provides that the affirmative vote of holders of at least sixty-six and
two-thirds percent (66-2/3%) of the voting power of all of the then outstanding shares of voting stock, voting as a single class, are required to amend certain provisions of our certificate of incorporation, including provisions relating to the size
of the board, removal of directors, special meetings, actions by written consent and cumulative voting. The affirmative vote of holders of at least sixty-six and two-thirds percent <FONT STYLE="white-space:nowrap">(66-2/3%)</FONT> of the voting
power of all of the then outstanding shares of voting stock, voting as a single class, is required to amend or repeal our bylaws, although our bylaws may be amended by a simple majority vote of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing provisions will make it more difficult for our existing stockholders to
replace our board of directors as well as for another party to obtain control of our company by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it
more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other
rights or preferences that could impede the success of any attempt to change the control of our company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions are intended to
enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of our company. These provisions are
also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy rights. However, these provisions could have the effect of discouraging others from making tender offers for
our shares and may have the effect of deterring hostile takeovers or delaying changes in control of our company or our management. As a consequence, these provisions also may inhibit fluctuations in the market price of our stock that could result
from actual or rumored takeover attempts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Section&nbsp;203 of the Delaware General Corporation Law </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any
business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines business combination to include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the
transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (1)&nbsp;persons who are directors and also officers and
(2)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least
66 2/3% of the outstanding voting stock that is not owned by the interested stockholder. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any merger or consolidation involving the corporation and the interested stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as an entity or person who, together with the person&#146;s
affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the information regarding our limitations on liability and indemnification under the heading &#147;Executive
Compensation&#151;Limitation on Liability and Indemnification Matters&#148; in Part III, Item&nbsp;11 of our Form 10-K as filed with the SEC on March&nbsp;30, 2015, which information is hereby incorporated by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on
The NASDAQ Global Market under the trading symbol &#147;SCYX.&#148; The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on The NASDAQ Global Market or any securities market or other
exchange of the other securities covered by such prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our transfer agent and registrar for our common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent&#146;s
address is 6201 15<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue, Brooklyn, New York 11219. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that are not issued at a discount, may be issued with &#147;original issue discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or
terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limit upon the aggregate principal amount that may be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maturity date or dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the form of the debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the applicability of any guarantees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount
thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be
determined; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest
payment dates or the method for determining such dates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional
redemption provisions and the terms of those redemption provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to
purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be
advisable in connection with the marketing of debt securities of that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be
exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#146; option) conversion or
exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to
such securities to be due and payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the terms and conditions upon which the election may be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#147;United
States person&#148; for federal tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on transfer, sale or assignment of the debt securities of the series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or
advisable under applicable laws or regulations. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or
exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include
provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of
our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the Indenture </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of
default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid
extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any
payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not
constitute a default in the payment of principal or premium, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure
continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the
outstanding debt securities of the applicable series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if specified events of bankruptcy, insolvency or reorganization occur. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default
with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt
securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default
specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of
the trustee or any holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may
waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in
accordance with the indenture. Any waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event
of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt
securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any
proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the debt securities of any series will have the right to institute a proceeding
under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within
90&nbsp;days after the notice, request and offer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt
securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file
statements with the trustee regarding our compliance with specified covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation, Merger or Sale;&#148; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence,
or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form
of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may
be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus
supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extending the fixed maturity of any debt securities of any series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that
we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide for payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer or exchange of debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">replace stolen, lost or mutilated debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay principal of and premium and interest on any debt securities of the series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain paying agencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hold monies for payment in trust; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recover excess money held by the trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensate and indemnify the trustee; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appoint any successor trustee. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must
deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides
that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in
the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to
global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and
aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the
applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or
at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange,
but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will name in the applicable prospectus supplement the security
registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a
change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt
securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the
trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the
request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are
registered at the close of business on the regular record date for the interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on
the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder
or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each
series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a
particular series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on
any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except
to the extent that the Trust Indenture Act of 1939 is applicable. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information that we include in any applicable prospectus supplement and in any related
free writing prospectus that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may be issued in one or more series. Warrants may be offered
independently or in combination with other securities offered by any prospectus supplement. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms
of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The
applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of
the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of
which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of
warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the
provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the
applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectuses, and the complete form of warrant and/or the warrant agreement and warrant
certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price and aggregate number of warrants offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency for which the warrants may be purchased; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may
be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these
shares may be purchased upon such exercise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any rights to redeem or call the warrants; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants will commence and expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manner in which the warrant agreements and warrants may be modified; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the securities issuable upon exercise of the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such
exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the
applicable indenture; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be
exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust
office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or
the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise
specify in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the
applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder
of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss
below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all
payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so
under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global
security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect
holders, and not holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in
their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial
interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we will
recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along
the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be
indirect holders, not holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of
a security or has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the
approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the
holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations For Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of third party service providers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it handles securities payments and notices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether it imposes fees or charges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would handle a request for the holders&#146; consent, if ever required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a
security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial
institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued
in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its
nominee or a successor depositary, unless special termination situations arise. We describe those situations below under the section entitled &#147;Special Situations When a Global Security Will Be Terminated&#148; in this prospectus. As a result of
these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial
interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global
security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If
termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial
institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order
for the pledge to be effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#146;s interest in a global security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in a global security, nor do we or any applicable trustee supervise the
depositary in any way; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may
require you to do so as well; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and
other matters relating to the securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for
an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will
Be Terminated </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged
for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have
their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we notify any applicable trustee that we wish to terminate that global security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a
global security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the
names of the institutions that will be the initial direct holders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated transactions,
block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at a fixed price or prices, which may be changed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at market prices prevailing at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices related to such prevailing market prices; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing
prospectus that we may authorize to be provided to you) will describe the terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of the underwriters, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive from the sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any over-allotment options under which underwriters may purchase additional securities from us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146; compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any public offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchange or market on which the securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters
named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used
in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of
the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by
underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public
offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the
underwriter, the nature of any such relationship. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We
will name any agent involved in the offering and sale of securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts
basis for the period of its appointment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional
investors to purchase securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions
to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide
agents and underwriters with indemnification against civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and
underwriters may engage in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may
offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without
notice. We cannot guarantee the liquidity of the trading markets for any securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment,
stabilizing transactions, short-covering transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions
permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the
over-allotment option or in the open market after the distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are
purchased in a stabilizing or covering transaction to cover short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters or agents that are qualified market makers on The NASDAQ Global Market may engage in passive market making
transactions in our common stock on The NASDAQ Global Market in accordance with Regulation&nbsp;M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of our common stock.
Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such
security; if all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market
price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received
by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, Cooley LLP, Palo Alto, California, will pass upon the validity of the
securities offered by this prospectus and any supplement thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements incorporated in this prospectus by reference from our Current Report on Form 8-K filed on October&nbsp;30, 2015, have
been audited by Deloitte&nbsp;&amp; Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report
of such firm given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_13"></A>WHERE YOU CAN FIND MORE
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form S-3 we filed with the SEC under the Securities Act and does
not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits
that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and
reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at
http://www.sec.gov. You may also read and copy any document we file at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public
Reference Room. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc202358_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; information from other documents that we file with it, which means that we can
disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we
filed with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the
registration statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File No.&nbsp;001-36365): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014, which was filed on March&nbsp;30,&nbsp;2015 (Items 7 and 8 from such Annual Report have been recast for discontinued operations as reflected
in the Current Report on Form 8-K filed on October&nbsp;30, 2015); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information specifically incorporated by reference into the Form 10-K from our definitive proxy statement on Schedule 14A which was filed on April&nbsp;22,&nbsp;2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended March&nbsp;31, 2015, which was filed on May&nbsp;15, 2015 (Items 1 and 2 from such Quarterly Report have been recast for discontinued operations as reflected in
the Current Report on Form 8-K filed on October&nbsp;30, 2015); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended June&nbsp;30, 2015, which was filed on August&nbsp;19, 2015, and related Form 12b-25 which was filed on August&nbsp;14, 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended September&nbsp;30, 2015, which was filed on November&nbsp;13, 2015; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K, filed with the SEC on January&nbsp;7, 2015,&nbsp;January&nbsp;9, 2015 (other than under Item&nbsp;7.01 and the related exhibit), February&nbsp;11, 2015,&nbsp;March&nbsp;3,
2015,&nbsp;April&nbsp;9, 2015,&nbsp;June&nbsp;10, 2015,&nbsp;July&nbsp;23, 2015,&nbsp;July&nbsp;28, 2015,&nbsp;September&nbsp;28, 2015, October&nbsp;30, 2015, November 2, 2015 and November 6, 2015; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our registration statement on Form 8-A filed with the SEC on March&nbsp;19, 2014, including any amendments or reports filed for the purposes of updating this description.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item&nbsp;2.02 or
Item&nbsp;7.01 of Form 8-K and exhibits filed on such form that are related to such items unless such Form 8-K expressly provides to the contrary) made with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act, until we
file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus and will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future
filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is
incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SCYNEXIS, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 Hudson Street,
Suite 3610 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Jersey City, NJ 07302-6548 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(201) 884-5485 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn:&nbsp;Secretary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g540762g42k37.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>17,751,500 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
to Purchase up to 21,301,800 Shares of Common Stock </B></P> <P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Sole Book-Running Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Guggenheim Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Lead Manager </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Needham &amp; Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B><I>Co-Managers </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="38%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>Roth&nbsp;Capital&nbsp;Partners</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:12pt">
<TD VALIGN="top"><B>CIM&nbsp;Securities,&nbsp;LLC</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;</B></TD>
<TD VALIGN="top" ALIGN="right"><B>National&nbsp;Securities&nbsp;Corporation</B></TD>
<TD NOWRAP VALIGN="top"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:44pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:44pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>March 6, 2018 </B></P>
<P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:15pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g540762g27k51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g540762g27k51.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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MP7SC'_/XP>X?$:9'='C%/2%1_>L%\XQ_S^,'N'Q&F1W1XQ3TA4?WK!?.,?\
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M *54)F;%7-#BCY1^.9+0D*4C!%@=#A3I# UUQ*FV)LI+27^S#K2%QEMOJM+
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M3[,?%YZ#V!^/S5^:I^PRW/\ Z3D?Q?1^#[,?%YZ#V!^/S5TNE^SL!]?[)@[
M!19.E9,B.FPG9:U]D,V1;A#4C6(4=#D\HY,:4,<SD<E,D.MJ/-PXE4AO*3=(
MQ[+_ $_;QT4\#D<WM_MXOBKYZI:A-K%)UHW4"\ CI5C#S=6CPNUUY@N5;DEU
MSB)-3[_GE15I9"3!E-8BM1FTRHN83:_^4S"G).>G_3]7FHPQCCD=K]O#5(>7
MU93BE.*4XI3BE.*4XI3BE.*5(NL;O9:398[M>BJ,I,J9$E*JMMZ1$M$20\E*
M!;T5C"G52E.JPH;*CHS,A3,MO1<YSE;;E" 1Q_\ ;PT'[#NU=6SC(@DIY-$4
MXC"XL65('2'6)$P%,DLI=D@I\J(IR%+FBG<YC2)$)UUAQ2?KH=PZTV!R/JSW
M?#52,?W_ !> UKO*U2LL+EE&U9ABY#T5R4ZTXX['>5%7W8R7%X4]*0M&6HL?
M"G)#V5+2RCP\/O9_8$*10@=)XX_;ZZJ,] [?^E243*1C0O8AV,KQ).44P/Y;
ME&6WYD5.<L$9ZDYPE:/.LP5%?=PK"5]UQ+3V.\I>,VCI3_ZN'<SQQ]=79X-_
M]/X\<":X5JRT6U+/;<4T0EP0R):VU*0ZZU%L4H?#<=4G.%*[T%AJ-VJSV*8C
MMH]J4]G*#H?N9/[?W4[:>' Z>UG'XN'[=LX]J2.P1V.-ERF8$TLJ;'&3I'B8
M82['L#4V1#<=;0YF/@A'CJ9PZO&&>W'AO+2AS/;7M(>T.GQ<#CP53ML.[G^_
MHSX:ZEV9:CP*2RXXT\316$^7.M97G"XRB4_(COY6AM:E)'>$EM2D_51<1\MJ
M7'\%62]LCHS_ ._@HW0/B/\ >>[Q_;A6@<OJVG%*WK7]K/5<]&4%:>G^7O,Q
M9(9'?4DFE2^Q#:$)PK*)2,JSF-(2G*FE9SA6%LK=;7:P!''M=NKE)!X>+NUX
M_?#ICR)W?/3L*&P7Y!8SKB4/@#$>&N2\1(W)Z-%@HRA:FEON27FXZ>ZYEM3B
ML=U>4YPKGTYZ@\L</)_E#-*P2*+:22R.WL4CCLE9V/@502? *\B]4E&DVILN
M-%+.]HR(HZ69KA@JCPDD >&O$[86MK#K0E$&6!P:^Y-06RQ)%2G)453X"QF:
MD<B96]'BO>,+L5?+#77,,YARLQ<3!LJ<.D1ICWMVS]I6^TXFEMQ(H0Q:EE0(
MVFXMH;N!\!F&);:XAE U:TUZ)52161?.[JTEM'5)=)+!\%#J&8I9()%R0#E)
M8G0\-)TZD+(58[-4-'6JYT1[8L$S31598O8?6JY-DL+8+*;G81)8X"%O.S8Z
M8,1@D,!%Y*#$V;&"0L074%",%:F4N8UYMRUL[]=G/#>2W+6$VTPMM;F<=16T
MT,$\H",7=HI9X5W$:/.^\!BBD .)H-G37%L;M7@2$7,=IJFE$7_$2H\D:$L
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M5&DF4*0J._)9RMJ)X;/D[28\9"VV$MLL=C32%H<2A.,*3C#G:O+2,8XX_O\
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MA(V=IP.6:3=WH]>$,Q$UKJZF*[N.)WYC:AB:X#V\^^MGCC:",GGVD>D8LY
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M;BB()J/(-31DZQCH$:46@K&#C$B:V%"(@JMSYZT+KR^PQZG/WE[W^))/.NY
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M2/B)%;DQH+1D,=2Q$+3^L1X;70@+7:$''TBMCPU/KU=(#RM;KU<%0QS \4!
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M"!=?H$C%9.=+>N16P+U>7#$XJ3JQ0+$&VZDMAARF9;Y<Z=P*D1HP^%.+M#<
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M]NK#[4EAF2PO#C$AIM]ES&,XPMIU&'&UXPK&%8PI"L*QC.,9]OMQC//H4$,
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M]N<\HS*JEF(55!9F8@*J@9))/  #B2> '$U:S*BL[LJ(BEF9B%5549+,3P
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M'+[5S5AM;1:93K;+%VH 6-5V*\*P(;DFZY=;)72F"@PHTL(15!BHBH984V"
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M.$J.X]&\K<*@4D@G)R...VS-V@.VQ_%BB0JC%@6)(8'./PI'E)X ?A.V.UC
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M/&A.&+H1LHAJHP3>)C:LU.S-@@*QV7LP!@67.S[<%@'1. ,&22\B*HQERPT
MYJT7&V&9U6\OF,;!7Q>2D(2DDG.(EP L<4C.Q.F,(VLKBMTI^SJU>W;#&K)Z
M9)(U,HR%M 4A!.5^P5TG*&PC,*,:KMAA"C@SSB'(P"PMZ8/9CE!DN//'NR8K
MJ7<W)LC8CZ@NRMF$J<,#L^V5E) (#*T(89!!&1Q!!'"K)+W:L>@O?7H#KJ1A
M>2LKJ"5)5UE*MA@5;!RK @X(Q7:-;!!UZQ4ZIF#<J&>O\PR.J,+,<L^V6G
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M##,.!P2,J=0X''!N&1W#@9'&LMRM4IQ2N\,_ND/_ ,NB?\0WR&X^]Y_Y&7_
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M;/MKF^BM]H26T:W-W:6UY>I"[20P37 A$DWP*ZQ1>8H9^R40H.R<W?L73,1
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M$#:M0X'(G"<.&8RPX-@6(QC.<XQC';G/LQC'MSG.?K8QCDQ(4%F(55!+,2
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M()T[LDC==)3F'M%>!&*Y)>3O*50FG9MTIC&E&&@,J[S>A0=YP"RYE7 RLA+
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M#E;R2!9AM2S#/DL=$V22P;.=UTZ@&STY /2!4AV!RH*HAL;TI'@(I*:5 4H
M!KQC0S)@\-)*G@36T1-*5B#,JI"%18,6=24GTU64Q&RT\%5;%^-:7HJDN8[T
MJS/Y5*L$M_Q91J6M<LD])DK6ZJX<K^2@*D;6M04U:3HFX:_98]:_"Z6[IXGC
M5AY-\I"'4[.NR)-.L<S#:/8 \_H0<$'0HX  5@XO3I2!\80/%46**$!2U5,1
M@L",RT+<>H3GE6OH#T=:7%( Z^)(CEZ/7(;L4%5BD*#+#CXJHC.$T'*WDH
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M%)<3D;1LI6,<"&1V*+<L\FA$)  8\  .BM=>H-%D0)(I^EU)\7-+2#TP:]7
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MC+JT7)7FT(N3D]ML^Q@QLYX%EN0=)NKJ;>2+U1-, -3J%];AX0("RHJD[P7
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M5JI]B&VW%8QVJ4$SGL2G'M4K.<^SMSGGQK+ZHO+!99%7:J@+(ZJ.H-FG@&(
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M)K6!K[5MN<%5.KCXHTS/1<[K7#=@;N=XCQ6DV6V1_ F/>3PU-,)=;ENSU5U
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M I*K[)C)(6D;TG9NR[?9L6B(:I6 WL[ :Y#W/XL8/L4!P.DEFRQB-[[/ ?\
MP1S'],@/GJ@]H4G]+X?R-/6&?;.GR#+^4(:M06G+%BB9-N!/*K'#YDY L4TT
M^4)+B1G)"8 UF0_&8>GS,MXCPVGI,=IR0XVAQ]I&<N)Y"M]53@>\NI4L2DTX
MST<6REVI\<<GB;K*VKJJUZ.0B(")S@S)2SA+##V8R9E&V0]?G@O1(PPW)+KG
M"[ 4!"R9J(JN!W?J/F_UJL'1UU [AZA >V:&4V])HG4E47PHW:NG=L:YKHG8
M^ARQ!\"R8L]*!A\H 6[7Q-E%VAZV.ND-CTJ>8&5V<_=+%&;L82>H1CPCM'M'
MS'NCI%8>9MGKT$].6TOBL,MN_K52NJ6W:[K.X]6T?2HW:%IZ<:>$A%C&R16J
MMB7#7NJKC?A.RHUFTDZ( .AX=L' Y-UJE?3.D#H\E5<#([7=SG'3T9Z<8XYK
M6AG6GL?8U+W6:TKM1^QC>G#X/?6'5A"NEPUW7ZW/W-LS;"]_F0U9V)3' \=^
MB5>N0.G>77[77*MFLVV$2NA6"H_&*U-F5(57'$9&,L5QGHQCC]?3Q!KT:KO4
MCKZRZHJVRQLV).)6VE4BU"]=C2XF==72FPA@>76*ED=F5'5&+D")P<(Q*)X&
MC(3KRB!:6-%1Y<R.JRJ):IZKM[7^Q:!TW:[ $!WK;'4Y\(=4KI=*2#%+9 :Q
MZ/MH;%IH&M4B+9QA89DJ1GKUH-?LMF!EI9"L"[9(4-AV$S"+ U7$ 9[8 7QL
M >./Q\ <YQT\:A?6/P@&_=W4SJVD5\F"J=QZ&.G;8%IM#J:V,D5W<>[J+OSK
M%U#$08B$V2$P)K,N.Z-'C1&#4"@4^TYM@A!@V2(_48+KJJE<:?XQ^HA2#\?.
MQW.%2KJGKPN[75LX%VX8&"^E?J!UH.L73Z=.#Q HEK;:-+Z>]5=2NQ]<VZQ#
MX8QDA!M&J-M$;94I!EER?"8TS=F%SI7CIPA5,<,]OMCP9(X?$1Q^,5,/P?W4
M!O#?UKZTGMSR&1L?6'4B*HNLZ$Q7AX*31-<V706E]V5X%;'4Q<F2FPAC6V5!
M+K,F$GAF"P=;0:!#C(4N2H1@+X1D]OCJ8?Z5-W7E]ACU.?O+WO\ $DGG7<@?
M;IR7^6K'[9:T/*;VO[8^3[G[,UY33_\ KTW_ "N3_OE\_/Z?]_F_E9/\9KS5
M_9M_U-_>:ZG(JMKC==:8:<??<0RRRVMUYUU24-M--IRMQQQ:LX2A"$8RI:E9
MPE*<9SG.,8Y4 D@ $DG  XDD]  [9- ,\!Q)X #MU!([J*UU\2 5_LA;%=!V
M:E+VF,2J :*R1>JW4P9$"[V_ H9+Q512QI&"4+S36(0P"AZ;%E$7D@RDYO:/
MLB\ZIEM(8][+!<]0OSXD$E\-0>VM];KOY Z-'&L6MY<(RH#+&E99LY]ZT*+K
M=)=P>*J&G&=44>IAO&# JH7+.<$*-:BN_P"L-J7)8P%;L!61/!G)-8(8ATB^
MS8>;)#'X+RJ^/*1*P\+,&V N4G'!0>9.G)!*2;\#S4I,S-G6B_W<<IBC"2Q"
M=-5S:JVY9]VLKQM.)(XS+ZT'D5%,OK6=YS:IU'<:5;0H#H)!F6$'06TAV4R!
MD4MS-3 #7S,ZN%?E#V_'ONR[E4@[(N=4Q&K=*;2J=M&SWY.+,'V_,VC'CK7&
M<B,-1H\9G7;$V \R_)\LC&$K=PPMKP\KK9YM;.WGD+K.]]M*QGMW0+N9-GI8
ML><&)8L;PJP(72T>!D'-);8PP12,6$C7%U;R1L -VUL+<GCDY),Y!! P5[>:
MCYCJ@"JW/L;6LF"AL/K0M4P!\Q!8+FY3,V]C:MBE$<I##YT?P[1=CAO6@ZNH
M2LXU8:::(2%)@.(88RVV)+UNLKU6)DO8[B6*-C'&I6T>?JE/7'5LP6T45Z\Q
MQ$8;F-%YX),QL'ZFAG!RTZR.BG2HQ"TF]7G$'UN)%G9_8Z)%4<>)WW;NSSFO
M;/H>OB!(DDSN/;3NKYLLC)F,.5]*-9;'V4DW%8C-K23SAC7$H/D<Z[!PITO'
MG8G)1!<BR\79]E%=P;4EDDD0[.V>+Y50*1,3>V=ENF+'*<;Q9-8#\(RNG+!E
MAMX$FCNW9F4VUN)P% .OU^"#02?8_OX;4 WL2,<<C0J%OZT7" Z#FUL &VL%
MW\?TM;J=@D1ECP\, U+MGQIC$UQ(LV1"/Z@2(V57')0R%'FNV(-5)#D67(44
M1E7>RH+=Q*LTLMA+LJ+:5O<:$#R-*5M]PR!F4-#M'>V4P5V91#). P709IK2
M.(AP[M;O9I=1RZ0"S/IC,9&2H*7):!\,2 C2#(&FMHB=1='AIO9&W$HU? U>
MP75@<09B&BZ_B9K:6.J5XO-I0*&S6ZK7PNQ8]P!.&2SD4-@17_/;L]MA)'R&
M!MCW3&U2W0RRSPVQ="T<8ZIO%>XMK6 NZ[^:2S:WE$4>J7>3;H(6T:HS9RDQ
M+&I=Y$BR"57UV8&2**/4PWCM"8FTKE];Z-.=(.;]8;4N2I@*W8"LB>".2:P0
MQ#I%\FP\V6$/\\2J^/)Q*R\,,FXX7L.."P\R?.2"4DUECS6M,O,?6F_W<<AB
MC"2Q"=-5S:JVY9]TLSHTX>.(R^M"2153>^M9WG-JWJ.XTJVA0&02#,L0.@MI
M#LI?4JE^9J8 :^;G5PK1I'4H.CSML&41!1'6>L-6ZHW.JWBR,F2\8US?X=_)
MG#[$14)MO&*Z#I*K##BQW)3IH>MR,TIB<\PA.4-C.5L(RTB7M[?7^S>IW0 1
MWEHUHD418,2=]+<B)F(41/@D,H),HL3BW4EEGN+BXM=VR@!9XFA5$)S^&\N@
MDXT'!X@$U:)*DJ3A2<X4E6,*2I.<92I.<=N,XSCV9QG'MQG'LSCVXYHZP*_>
M*5D0_P#=87_G&%_Q+7)K?[X@_EHO\:U?'^^1_P#6O^(5_0/S[2KV6G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4JL_51KZW;(H 8)
M3!/G@G$M\$I(C>7C1_AP60QV(X_XQ29"85W9$V,WX:'5/9\3O);RA"U)X/U0
M]B[3V[L6UM-E6W55Q'M.&X>/?00:84M;R-GUW$L2'#RQKI#%CJR%P&(T7*&S
MN;ZRBBM8][(MTDA77&F$$4RDYD9%]DZC .>.<8!Q0;U4]]>XN/Y35#]?\\:^
MYSRQ^"!_6&S/TVN.['ML=Y_VBU_/T]5/?7N+C^4U0_7_ !]SGEC\$#^L-F?I
MM.Q[;'>?]HM?S]/53WU[BX_E-4/U_P ?<YY8_! _K#9GZ;3L>VQWG_:+7\_3
MU4]]>XN/Y35#]?\ 'W.>6/P0/ZPV9^FT['ML=Y_VBU_/T]5/?7N+C^4U0_7_
M !]SGEC\$#^L-F?IM.Q[;'>?]HM?S]/53WU[BX_E-4/U_P ?<YY8_! _K#9G
MZ;3L>VQWG_:+7\_3U4]]>XN/Y35#]?\ 'W.>6/P0/ZPV9^FT['ML=Y_VBU_/
MT]5/?7N+C^4U0_7_ !]SGEC\$#^L-F?IM.Q[;'>?]HM?S]/53WU[BX_E-4/U
M_P ?<YY8_! _K#9GZ;3L>VQWG_:+7\_3U4]]>XN/Y35#]?\ 'W.>6/P0/ZPV
M9^FT['ML=Y_VBU_/T]5/?7N+C^4U0_7_ !]SGEC\$#^L-F?IM.Q[;'>?]HM?
MS]/53WU[BX_E-4/U_P ?<YY8_! _K#9GZ;3L>VQWG_:+7\_3U4]]>XN/Y35#
M]?\ 'W.>6/P0/ZPV9^FT['ML=Y_VBU_/T]5/?7N+C^4U0_7_ !]SGEC\$#^L
M-F?IM.Q[;'>?]HM?S]/53WU[BX_E-4/U_P ?<YY8_! _K#9GZ;3L>VQWG_:+
M7\_3U4]]>XN/Y35#]?\ 'W.>6/P0/ZPV9^FT['ML=Y_VBU_/T]5/?7N+C^4U
M0_7_ !]SGEC\$#^L-F?IM.Q[;'>?]HM?S]/53WU[BX_E-4/U_P ?<YY8_! _
MK#9GZ;3L>VQWG_:+7\_3U4]]>XN/Y35#]?\ 'W.>6/P0/ZPV9^FT['ML=Y_V
MBU_/U%UYUU<=;$H@BZ"/,Q"=!21BQ_+QA#Q8:GWXV'O%%S)K*.U^,\CPW'$.
M_4=[N=Q259Y[:^P]J;!GCMMJVW4LTT(GC3?6\^J(N\>K5;RRH.>C#2S!N&<8
M()U]W97-C(L5U%NG=-XJZXWRA)7.8W<#BI&"0>'1C%:3S4UBU.6EM$V?<!7&
M8R7!-4A/I08LC[.5,H[.Q2X(QM7=Q/)K1G&?"2K#$1"DO3'&\+8:D==R5Y'[
M0Y3W&8P;;9T3@75^ZY4=!,-NIQOK@@YT@Z(@0TK+E%?;;+V1<;3DYN8[=#B6
M<C@.WHC'#7)CM#@H(+D94-ZZT:AUC7-?C5NJCD0(#'8MYW/8Y-(RLI2EV>2E
M=U*Y4Q[NX[SBL)0VC"&([;,9IIEOZ6V1L;9^P[*.QV= (84XNQP9IY, --/)
M@&25L#+$ * $14C54'I%I9V]C"L%N@1!Q)X%Y&[;R-@%F/=Z ,*H"@ ;CS:5
ME54=[[/ ?_!',?TR ^=>/:%)_2^'\C3UH3[9T^09?RA#5N.<A6^K#V(*U9*^
M=KS\XH+9/!R85XD#G.##0YHI"?@N3@Y)K"G1Y2(A_,@?.;2IR)+;9?1C*F\8
MXI5+\]$3,B?LZV/[_P!S#MK; JIG7PC<M;BZB$WZAT:R':M8[3"KD9[5<^BN
MGK:2J(?!HX9I91(Z/$9S2X%2FJES)2JY[7:[G'N8[M;K2NG#9M'$5P1%ZQ]_
M6%L"6=6\NQTGI0AQ)]/17F00>A1Z_K_INH55KP:KR6W;  )UP$+L;I24H?:"
M]FJD )6Q*A(/X(__ '=WPL>GH_7QK5C/07IV4#-UJLD[C10MWZ?(?2[L]FN$
M1ZI^QM/0"=L+PX1HR4%SRD"WQI>Q-G(9O 63 -I:V=<Y2E+.*K!JL*9/Q\<\
M<]/[8\0J8SO2QTQVD9*#6GIUT9:!4]H4P0'V74U#L$0BT#0PV&219+@9B"&1
M2(T=(]4S#ZXG@-984C+:<X50$CH./BJ!M;_!T].>DVZY,TC78>J;34-U[@W?
M7;34*K00LI@INN3=D6BC%1H6IB1)S6HFOW==2I]<GQ%3JS7ZG16H)ORVLQIK
MJKBQ/B QVN ''X^&?CKA9^#NTL)JMDI]4.WRJC=D:9-:'W5.&$0F3NX:/9;O
ML+8]B(V@JX![PF]%KEN'<I5=MJ#%>=A9VY=O-D"%,;I\ZHJIJ/#P'(\'0/\
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M^E3KA9=\1^,^:GI?UG[Y!_PCOT/'6/:W>$_B7TJ=<++OB/QGS4]+^L_?(/\
MA'?H>.L>UN\)_$OI4ZX67?$?C/FIZ7]9^^0?\([]#QUCVMWA/XE]*G7"R[XC
M\9\U/2_K/WR#_A'?H>.L>UN\)_$OI4ZX67?$?C/FIZ7]9^^0?\([]#QUCVMW
MA/XE]*G7"R[XC\9\U/2_K/WR#_A'?H>.L>UN\)_$OI4ZX67?$?C/FIZ7]9^^
M0?\ "._0\=8]K=X3^)?2IUPLN^(_&?-3TOZS]\@_X1WZ'CK'M;O"?Q+Z5.N%
MEWQ'XSYJ_<;>UIG.,8N(?.<Y[,8PX[[<Y^MC_H>62[(VE#')-+9RQQ1(\DDC
MZ51(T4L[LQ; 55!9B>  )J^.\MI9$BBF5Y)76.-%R6=W8*BJ ,EF8@ =LFNQ
MZ4]?>]0S_6?^AYS'7W8OPML[Z9;_ )RNB['=O? ^T?HDWH4]*>OO>H9_K/\
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MN/Y:Y"F8B-NK0[(3$DK:0MMAU2;M0U%<\X $CN D@$]S.#CNX/<JF#C..!)
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MH4*YB8K*TEKNY&1 60R2E@H)X()-(":J2S!TD;&=<F8263>*&0+/K4%FPP5
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MS,=!S/);.H]8B4: L# D@MEAD2#(J..:(*59"@,L,GK8U?O23*3ZXYYQ,H.
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M<4IQ2G%*<4IQ2G%*Y&?^E:_\1'_JQS5;=_@3;/R5M#_*35LMC?PQLKY2L?\
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M$WVC51OJ+Z3JGU)W'2%HN1R2R.TG8[-8HM0R&$EZ]=L7"L3*980=Q8)H=<E
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M6QL8["+<QN60$A-21AE0LS!6=5#2%=6 SD\T+PSDM2YN7NGWC@!C@MAG(9L
M%@K,575I!(4#CX, 7HUG_?#I/^E 3\8,<MVM_!FT/YG<?9-5+3[ZMOYQ#]HM
M>I'/'Z[BG%*JI<.G,A9[.<L#5IAQ&RY!Z:B,L8^ZMC#N<9PVIQ,M"5YQV?VV
M$)QG_!SLK'E3%:6=O;-9R.8(EC+B50&T\,@%,C/<K17&R'FGEE$ZJ)'+8*$D
M9[6<UK?JJE/?&!\T2/T[F7V8P=XR_/)Z%0]8Y.^$\AO2IZJI3WQ@?-$C].X[
M,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X3R&]*GJJ
ME/?&!\T2/T[CLQ@[QE^>3T*=8Y.^$\AO2IZJI3WQ@?-$C].X[,8.\9?GD]"G
M6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X3R&]*GJJE/?&!\T2/T[
MCLQ@[QE^>3T*=8Y.^$\AO2IZJI3WQ@?-$C].X[,8.\9?GD]"G6.3OA/(;TJ>
MJJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X3R&]*GJJE/?&!\T2/T[CLQ@[QE^>3T
M*=8Y.^$\AO2IZJI3WQ@?-$C].X[,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8'S1(_
M3N.S&#O&7YY/0IUCD[X3R&]*GJJE/?&!\T2/T[CLQ@[QE^>3T*=8Y.^$\AO2
MIZJI3WQ@?-$C].X[,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#O&7YY
M/0IUCD[X3R&]*GJJE/?&!\T2/T[CLQ@[QE^>3T*=8Y.^$\AO2IZJI3WQ@?-$
MC].X[,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X3R&
M]*GJJE/?&!\T2/T[CLQ@[QE^>3T*=8Y.^$\AO2IZJI3WQ@?-$C].X[,8.\9?
MGD]"G6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X3R&]*GJJE/?&!\
MT2/T[CLQ@[QE^>3T*=8Y.^$\AO2IZJI3WQ@?-$C].X[,8.\9?GD]"G6.3OA/
M(;TJ>JJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X3R&]*GJJE/?&!\T2/T[CLQ@[Q
ME^>3T*=8Y.^$\AO2IZJI3WQ@?-$C].X[,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8
M'S1(_3N.S&#O&7YY/0IUCD[X3R&]*GJJE/?&!\T2/T[CLQ@[QE^>3T*=8Y.^
M$\AO2IZJI3WQ@?-$C].X[,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#
MO&7YY/0IUCD[X3R&]*NK.Z8B0V%+(JMT%U(^+(FJ:2*?2IQ,5I;^6\*S-SA.
M5X;[N%9QG&,Y[<XS];FNVORMAFV3M2(64JF79U[&"9D.-=M*N<:..,YQ6PV3
ML61-J[,??H=&T+-L:#QTW,9Q[+P5$X)>&2H^5B0PPY$GCWVL/^6XPXM$V/[,
M+@,/OM^&G.7G%HPEW#3:_)\.2<M,N?(MFVBY@D#HC13P2+KWW.(FCZ# CR#2
M,NQ4!]"MN]4NA&^L+X:[2XB,;R++;W$;Z-QE5:"3I%Q)'&VHX10QT:F&\*Q:
MW78+HI]3@]3[BW5>')QA2G+.YC"<*:SV8S:&F96/;G.<XC)RQ[<=N?$[V,9V
MURY:#>,6.EP,MM)L#*X'_B2)(/\ ](%.Z<UK]BB,+<;M0HU1Y&G92\</TC93
MO%\Z=YW!IQGD!MON 9284R'"6I4YLD_Y./:DI@^1./--+(2'_+\MR7V,1O(X
M3+6'O';PER>_VQ&*V8=K*40S0PGUX7+F.!9!!N6=5-Q(_5&F1T$8A@C4.9%
M:>3UJ.EZT:W\)G@FG $#6R"2X>,S[\(SBVCCZGU1))O=_.[F,1L2MO'B:3'4
M^B/[$+* QR+0M;<-XCF2]'7)1E,=;+.6O#0ZUG"E9DX5A7>[,81G'9GM]G8^
MI5M%=E\II;EHFF!V5=1:58(>=/:-G)!'#1C'AKE/51M3=\FXH@X0C:EJ^2,C
MA!=C' CN_54G^JJ4]\8'S1(_3N?1?9C!WC+\\GH5\]]8Y.^$\AO2IZJI3WQ@
M?-$C].X[,8.\9?GD]"G6.3OA/(;TJ>JJ4]\8'S1(_3N.S&#O&7YY/0IUCD[X
M3R&]*HFVAJN5K+(3$DPP6\]8)91X$-R+Y/YN\@[W>\1][Q/%\N3V=G=[OAY[
M>WO8[-SLC;*;6ZHT0-#U/NLZG#ZM[O<8PHQC=G/3G/@K O;%K+=:I%DWFO&%
M(QHT=TG.=?U5%&,95G"4XSG.<XQC&,=N<YS[,8QC'MSG.?9C&/K\W58-6.US
MT]&['X!6VYD5\*KNN-P>[A)N>WGLSCL:<2I(QE6/_O93:Y.<8^HAX0M#^.5V
MIRGM[75#9:;J<<#)G-O&?^H<9F'<0A./&3(*5N+39,LN'N,PQ].CHE8?$?8#
MPL,]Q>(-75KU:!U4<V* #8XV$WV9RAA.?$><[,8R]*?7E3\I]6,8PIZ0XXYG
M&,)[W=2G&.!NKNXO)3-<RM+(>VQX*/<HHPJ*.TJ@#MXR371PP10)HB147I('
M23C&6)XL<#I))K.<QZEJH[WV> _^".8_ID!\Z\>T*3^E\/Y&GK0GVSI\@R_E
M"&K<<Y"M]3BE.*5Y_P#21>;[:^I3X1RJVV[V.SUK3_4CKNB:Q!F),5R#3:I8
MNEO1&V2PD=Y-#BR):9%TV%9)C<LP^3GQH+L,5&E,CX3,?"KB!A?""3Y3#^X5
M1X[N'J[.;XZ[J#H.\[AMFT=/]9'3?4-*4B74!9?1(G4EQU!TU[)W&&VO=3E+
M\Q"JQ%'7K9YYMR/?1NVX65 A]$3/P@8&FJK@84GMJ2>[G41P^KP=-6(ZA^MJ
M;J'K(TN$3L:@Q=$#M@U[IFWG1Y14$W>F-G]0X. ?U?LQ,"5-;-,5'7EDC:CH
M$HA$90'DXZAK;,**=>U^G,)5 ,@]W&?Q X\Y_%X\W79NU]I=>W7'IMC?>U:#
M3]7Z/Z-[EK*)45T>6U3+;N*1U,P[P78@72E6T8=9(^C&HO-!K-#,!H*XDSS?
M"AX(/\4( 53CB2V?Q8Q4W] 6^[WU'=-(*^[0C@_2'7]A;NT[<#55@OC:C<SN
MB-S7O3<R_56!)ESW((6[*I&+(V-Q-F,B)A&8(C2Y<> U)=48 'AX#XP#C\6<
M5<_BK:<4JI?7E]ACU.?O+WO\22>==R!]NG)?Y:L?MEK1\IO:_MCY/N?LS5:=
ME?WPKO\ Z5'?QE)YV>ROX,V?_,K7[%*T=W]]7/\ .)OM&K2>9]8]>- BQ[<O
MWPAG6AHR/8]R2]=AG>F)D"9K6U+2$&=/_P ?-&[6NANW#@$:R1&C+-FOE6J@
MS .8.+UR,J8XS(APASZHTK0(T\NU=HVVNX,*]1:62=U6TWEK<2LX4.-0DECC
M720R#." #@[9EBCL+*?3$)&ZIU!HU)GT3PQJA.GAIC=SJ!#''23Q&?A_":VB
M2EE*].@$.O5GK[,8[MX(J;3/Z'SC0KR;.<U;"O(]CMR67O&[/&JRTNH\(\G*
M,XNZ\MWNOL=JG]]/3LQ@,?O8X39''\#N/5IV<,\)C[.P7]['1>J6S[/ICQC^
M/_%KLT?X26]VILG#(:0"#"#,KH2F9+BKP2/UNJ4WK:!DRC%LN&9%3 $E,ZQ>
M"R&"\4:TF*8=*BD+*@A\<F;81[8D?(-LJG_PPZEE+)''M)21))F-#B$J=0 P
MVI060!G!]GHF#OB0>KA@QA69[(@:5Y[#UT$8SQ&#P8D+7!8?A+[U2:/0+;L#
M0,>GG;!6M;V^R:XEW I(NHD#L?J.C:!@3)8J14!A>F0TPIX[8  Q>08P1=<3
M5T<3+B'1I.9&-MB2..*26UW;.D,CQ&0F15FO.I02IC5HP 1*K2JJRYW2D,K$
M479Z.[I'/K :15D" (3%;[]@#K(<Y!C(1BR8WA&D@&4NEF\W>[::ZX%VJY6H
MU*H_5AUCT2GDY=A+>>:U4J2=DQ:D$#&VI;9:#%KT="6Q:F9J9$;"<92]G/;G
M,UG++);[2+R.QBOMH11DL=21QL1&JMG4 GX/'(JRY1$FL]** ]M:2. !AG=0
M6)'0=1Z1C![E4ETU\(1N'4W2#TYFBE:8W9<;7T8;ZZJ;E<]C;+LD$T0?T<<'
M.' B58K5K5)?L(DVQ&#]R0*'"9,3M7'7'5EM6NM]JSP6%HS)U3))LZZO7DEF
M<,3;%6=?WN3.M7PO%0N.Y69-812W=PJMN42\@M42.)2 )PP5O9I[$KENDD'I
MS6Q.]9>PP74AO'9]A.W27106PNAW46K-4"[&XBBC%]6^M:X3<,7X*BORU%DU
M1^RDK<Y."R@YXI8APJIME< IC#@^\[0E6\NI7:0QI+LRW@@5\1*;^)"6E70=
M6@N9,@JS,JQZM)&FSJ1&MX$4)K9+V664KSV%K(P 1BPTZ@H7!#* 2^G55T->
M=8.W-F[/EZ?$:&'U:_T*KZLM.WJ[>+]%&S!(K9=UO]1DEJ<Y &3V#PRGCJ.Q
M<)K<A48D79LHRI>2!3T:8\G8PW\\TQ@%J$EB2!YTDE (6>25"T9"G4L:Q"0Y
MP6#B/",":Q)+2..(2F?4DC2I$R1D@M$D;X?)&-9?0,<!I+Y92!5&:I\(9L01
MKCI-ZBMR0SM@?N&@.O?<INJZQM7Q<J)2+IB=6B(P#8Z1+K!+!F4/@S(@2F&W
M+-"748#90T=7:)):4Y&U<>UI1!87EPK,9+7:EPR0/HC*VY0JKQ%&U$ A8V+C
M=C4S%RQQF-8(TES!"54+<6$(:5=3@S!P65PXTY(+.NDZSI4:,"K(ROA&+LW?
MP.HX.HJO,OQ/>6A=.39TJZFAU,9:ZANG,YOZLV"(19J!4F^_55UTM4; %4/P
ML@U@39HDX<@QD&-S#M:3>K +=3*;JUMR3*RQXN[1KI'#;MF.C0T;+IYV X*Z
MM"P=0)H:7>L(Q!/,,("^;>X6W92-:CG:@ZMGAQ0@E=1[6B?A)INWI73/\8-4
M.ZX#=153KLH%:I\JPV*E3MBR[3?P%IUB/N 2MK&5ZV"!E)@6>K"[VT ^/PRS
M/1ADP>0KC;%ENM=K]4&SU0&%;N-2KL7:,S%Y4> 2*FE)$$8=%E"[Y9,*4*>N
M6SV&ZZH"R[PV[L&4 *XC"QLLI1F!9"7*L8]6[*Y((;*^J_-U6NK>-9_WPZ3_
M *4!/Q@QS7[6_@S:'\SN/LFK(M/OJV_G$/VBUZD<\?KN*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2L+9/\ LZ?_ ,RE/^!?YA[1_@^^_F=S]B]9NS?X1L/Y[:_;QUYU
M5_#F#(M]+;SB(Y(<ZZIAN2XIM.9K"$YSB(E4C'>6I*$89_9EK4EMGM=4C&?G
MZQU"[MG"N1'<V[,461BHWR '$0,F22%71SRQ"IEB!7T??Z3972%D!DM;E%#M
M&H8[B0D9F(CP%!9M?,"@L^$#&LW<&%L+@)7%Q$RI$E6$8BV6+WL=YG'?[MFE
MRY*_;]3WHRTL8[.Q2<N=[.<S:R,C0!HMUE7.G=;1BSQ7CC:,TSGN>M$(,<1J
MS6#L=U=9RLN]PT8U&79DN.#<,[,AAC'Q2@OW#IX5F_/572.\%N6EH@W!\DB2
MFZ; 0N*RY$PW*C8F-ED*E/R7D]F#DX?)(QDO278K;2W<)1F]5[,%MH64)<+!
MNHI5V1 #&C1!98]\+L-*\CC'5TT$ES&'D>)49@JX1LMJ&YUM$7MFGWTT+[9N
M&$KK,6BEW)LV$21(<]0P7,=M*4B25F5-3;'T^_\ ;I__ $?(?\4.YL>0?\-R
M?S"?[6WK5^J'_ ,7RC;_ &-S5UN>QUXE3BE.*557J."O6$UK4-'ECX+L]RRL
M(EE9;<&"SG/F#/:](<[>SM[.ZVVVEQYUQ2&FFUK6E.>QY*SK:P;6G9)9%C6S
M8I"ADD;[Z]BH\9)( &22 *T>V(S+)9QAD4L9AEV"*,[KI8_%@ 9)/  DU(FN
M])U>BX9GOI2=L2<85DK,93X,-S]OS7#SE:(O=^MB2M3LS/U64O--N99QK-J;
M?N]HZHU)M[4\-RC'4X_^<_ O_P!  CZ,JQ :LNSV;!:X<^NS>^,."_R:\0/^
MHY;N$ XJ9N:&MC3BE.*54=[[/ ?_  1S'],@/G7CVA2?TOA_(T]:$^V=/D&7
M\H0U;CG(5OJ<4IQ2J=N=%M%:L&^;&%V9O.I3^I6S,6[;V:A?XU=6<-0Z/7=:
MP) @D/K[9RGJ'T2IURN1'Z@5"3$,"8Y!<IPTN03?57/1X.CQY_O)J2=1].=
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M-<JD1:1#O?\ A9[>0E,'AK(XYTZ@I'TC?1O);N8YIHC&KR$0):N\P6)QN?\
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M4"&J!.C'@+^^M[RX36HZY;GKM5:% \JV,ZZ* 5(W(E)K$<8[$<"BYD\3#=1
M(3F)"FHGQYZ!T]VKZLMX9::92IQ:6FT-X6\XMYU>&TX3A3KKF5..N*QCM6XM
M2EK5G*E9RK.<\52N3BE5+Z\OL,>IS]Y>]_B23SKN0/MTY+_+5C]LM:/E-[7]
ML?)]S]F:K3LK^^%=_P#2H[^,I/.SV5_!FS_YE:_8I6CN_OJY_G$WVC5I/,^L
M>G%*Z[$2+%R_F+&CQLRI"Y<G+#+;.9$IU*$N27\MI3XTAQ+;:5O.=YQ:4(PI
M6<)QV, = QGB?C[M,_5PKL<4IQ2G%*<4IQ2G%*<4KKOQ(LI4=4F-'D*B2$RX
MBGV6WE192&W&DR8^7$JRS(2T\\TEYONN8;=<1A7=6K&6 <9&<<1X#W13/U\*
M['%*<4K>-9_WPZ3_ *4!/Q@QS7[6_@S:'\SN/LFK(M/OJV_G$/VBUZD<\?KN
M*<4KRIWV*>.VC: 2.1E!WS+A\4P7@Y[LX4\0ANQ&R,//>1V2H*WDR8^>^GL>
M:1GO)^OCUO9 +;(LE#%2UH@##I4E2-0\(Z1X:XN].+Z<X!Q,3@]!P<X/@/0:
MHOJJL;7UYT]4+5V-9AF=@Z>U8%U]7[)",UB74YUAKU8B4D;:Z6S,DLF614V,
MVX<*C+-!JI")!7*!,NG'5ID29H$GBM(H-TN]MX$B5P4,9=$$2O&"=07 U%7"
M$+S!J-62M%).\FLZ)9&D92&#!78NR/IX$@\ 5+ D!N;VH!.],.Y*_5+WIZF8
M;GZ^([ZZ2MZ4.Q!Y%=!SZE.H&[]:7W>0L>$M12Q1\OR(>KT;#KLPLV6BV?9M
M]MC!J#!$I:D2<5K*X6.6WC.J(W5A<Q.NE3&8KJ&6Y4*[..(@WR%M0>>:0, N
M"9UN8RR2OG6(+J!U.IM8D@D2$EE"]N7=L!@K%&A#%CP[%>Z=]OUB5HR.1!F)
MTW6&P>HNP7W86O;96(-@V=.VO!(.Q-G-0+@5AL@;'="YI\K<:DQX "HE&YXR
MFY558P"-BJVLZ&V!4DPRW;RRQ.@>8SAB)P)" DDC-F2/V$;:EC];""C3Q/OL
M, )([=4216*QB+&8\H#E4"Z4;V3#!?G%JD8!I_:L'<5&V(""$J/B22K$+<(X
MO= 5XH]_I #4S@80>)!G64DP74!6+5YKK$:VT>()#&JB*>38C5@')"B!LRP3
MBXCF16BRR"X#2K+%+&L&E6*XU+=(^E!)&%5HU.MW70BQM+&8G1B'P&,15&1X
MW:7)4'H:!DRVAR2'/-5#J8_6Q]';-,;DL%OULU.IL2Y22XO9+TRU0I^O[_7%
M:+)5&LW:%7U9>MNO]YUJX/ :A#L].0(A%-:A)"K,4-NHKX04EMIFN&DAU1"3
M4LV9 8I4-L424)[.*Y231&'C #0*=9?F*I)HQ"J28?1@Q\SGQMO@[)J]A) R
MAG*OJ(E;FA><QB?&F>L,=6H *D&3%9FPP41X-(,[<(S@H*3CH^L.IV*M*@-S
MCGBM#]\0ZY?E.QAY,,/S-CVL4@D<BDQR(.I[\(J1,R$*"I:<E4/6YX!&1EO8
MW027(#*,B0:F#"I-[:DDNH;)(.F( L.JUEU X4 F LG2#PT$A=)K,1]=;+"W
M=3(TO:M=']O;SLE@^([NPK.<GD=('-$ZJU]L4R5- "I@,-V#KJS5B%9*%8RI
M>>H:ZVQ70<^/FW*89NW4RR<"\33W3MNS*[%K9K6WAF9F4LHFBD0/$S,VG&E6
M&\(JF\C*<0KK%"JZQ&H G$\LD0"L QC=&*R*%&?9'@F3/6Y:/M@M<[44U^47
M#F'M&XI]$G+ES84>OVP7=LV.VCGS,-F3-K+VSJNL,(AVF&VX\(ET]N?E:2,0
M,S+RKB.=GD:)L%K?1%DD!'$FJ0:ADIOD*J' RICSTA<P1/$$57&<3:G& =2E
M-*G!]ENVU$H>#!R.@DBM-KHF\)^Y7Z(-O6S0J[14]BWK6$-O;%B9C:J1$V%I
M%->D7I$.VJA7Q@?-;V28C5B3\;X<JLGL:]RT[7!JW1F&\=T;DQB69=<<TL(W
MSX@Q+;:-[A\2\X3-H.L%'W/%%R,A'A$6LQQL%:-)/6E]<RD^O=\S*9&Z!8:#
MK&\X,W'8/0GU,E!H+%ALVT5G4VDLSL5T7OJ6+KUG@C]-;_K0JS4(?65U K4A
M%DV)<]46.56YQ5+PQ^KQ$M#(B:?&+VN[J>\*KJDFUZVWQ%R51P+>Z4/"$T-&
MKS20/H8\W0,*!&&>@FMU+:4CTZ1N\P@E2TT#%9"VL.RQI*NH+QU'B=9"3(8U
MUO8Q6=&JL1(%:S5/NVJK4:')B( SPTBO4>P"[C*-6IVR&8UK>GV,G%>9D!J\
M*<CL8E.M02>5HPC):*Y9+764=HY('88TLNF)UD+N7<29=@1I1<#/!NU$'A#3
M:0RJR2JO;!U."@50H*X4'@S$>$=NL+73KU16EAV;;IMO#V&/4]CAJ&8%[L--
MFZ!9;WI;IL"AB"[*/LWGR?4Z_N35FQK2?@R9ME<,Q["(*2*U8I!4R*%X/4EZ
M_%S(KB*9(F6Y?7$\MO9*K:P^HQI<03.X)?4&4E'+,JY&_MUP%",NJ,R*85*R
M*DMP6&DK@.T4L:J>;C21K7"EI43I?J!*8(YN9&SV@RSOK5=D5*F[#"2M?E*-
MK_J8'[5%6"GT=0V#*IQ>#K:-\7S8Z00Q(D&H0T+%^,8B#!LL6?J:Z;5O&D=N
MJK=\M*IA,45ZMP&CBT@QL(1H9<\6"J-:@.(C+ "I154;F53A") [VQB(=\X<
M;PZE.."DL=+$K4R[>';BV7KS7KU7$V^E29-NE+V?4JO?1E.OV:;*JMXKC6*M
M<WHCHYF= M1"GW%#<A068\&'2/#?B&X[0>7D3BXFBB*"2,[SUY$E6.7=E)$P
MDF"H(<QR<=)*J>(;FF.(Q1O)J*/S?6F="T>L.C<].G!4.G#4,GMKSA7.YZ+Z
MHIV-DO@+;L?!4I7=WP:1*3O6PQH4&PD=5ZF@Z>*N1(A\&*CL#=J5J[&WW(]:
M'(9A&)/E8%L::EA&\22VO3ORDDH9DN1%_P 5)I5S! +=L!D4 3I*W!!@,<J%
M8K4R36XW>I(R T)D]97)42S&09TDY,3(/9<2 0Q*ZJVN=J#J'/$+$X</[/96
M3W.'?F. MX.@*S.TVC=,ZV1F:L'K*Z[8JF8':B(NT:UM(L,>20*Q(<<<Y9(4
M<=9!,A@NV9]33<ZY0Y6Y*)U/U29 $5-#HRV[&*3G LP&-8"NM!+  N%BX0MT
MPY;?;D*=1;4K@RJ'3(P 23H.5:+ZHC=%V,;-^)5EVX>4-ODV$^,7LD>&:D:W
M$[PO1%\!#<,7(^1H>T\TZQU>"&CVZAZ^DF:CKU->+%E8(RC:84ZHD:;=O<,1
M*1I,P4;E;F0E5U2.8I]VZ!1)%"62$(S<6>KVW2"+4L2ZHP<[LMZYN8QJ.% >
M+6K:M#R!7D+!> 6MN):1ZKASI5=)NUW\ZM><!5:*7G=)BP#<UWU36J0+18H[
M*VASI]W?XT59B=I'T))1B8X4MT1B2H@0&D;S;7HU;N635Q5&EN&9='6_=#6!
M@%^JU5VD$6K.J0 ZF4VB6V.G7&F.!;1"H(;JLN=.>..IV9 I<C&%., B2&Z_
M=W=H:G'B3M[I\LQ$L!/:^L#>U+O=L@*&[9(%U!VN"<;G3*\R8;N5-D:K2*@&
M<*<HNSS&$RY4"KP S,NF0S0!6EC+!VGA:>673'K617#9*:A)'N-*L/6IVXD(
MJU&63=RY". 5$4BQ(F7TE&4C ."K[S)'LXAC!8FL)LL%L>[]35W 4FS; %?%
M:B]+5Q@N"MDGPE.',IV/OKTMA)-/8L\ 07,["UZ) U-I;@66@(0GUBURIX&8
M-$DWJ3)-)>2+&\RA(K*0:9G6,>O76_4H'"LTT*K&.:=)*2%E(4U<C1I;(S+&
M=4ERAS&K.?6K?=$.5RHCD)?V0U .F&#,*ZE+T?U&"0M!%$[O<,D&:ITNR#1T
MCMJVV%0FWTNWRB75-"L396PD7+'"VU3I"@-2DPFRD*$0D(6B!1L@1)IZD=M=
MJL2M+)D1V)9C/(Y$D4A:]#ZG.L7$?,C(# ,<XBTJQ/+;DR,$3BUR HB1<HZ
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M>FMQW8<I;C*7>S.$+6A7=4K'9[<I]F>=I8\J;>TL[>V:UF=H(EC+*Z ,5'2
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MQ\#^(X)_]ND'Q@:WL;X1?:-5T^;W)7-?TLN-FZMZZKL"JTYJPL'=?'^BZUS
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*Q2G%*<4IQ2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g540762g42k37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g540762g42k37.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0DF4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              5P   28    & &< -  R
M &L ,P W     0                         !              $F
M5P                                             X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     !HH    !    <    "$
M  %0   K4   !FX &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1"  A ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MH2P[+B=SOWK?^H72X#[[,.I^3!N(]Y @'7Z4?R_I*;/ @1F2"9 'A'BUN4R
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  -@ N #
M   ! #A"24T$!@      !P (  $  0$ _^X #D%D;V)E &1      ?_; (0
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0("
M @(" @(" @(" P,# P,# P,# P$! 0$! 0$! 0$! @(! @(# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\  $0@
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M:.5KP\TNO%&=R(W\-<)YY1.S<K74R0GB%US=\XQSD17?%517/!3]?#5QEJ_
M_AV^A5&)I\?^+9Z5;EJF5PH3<X]5+GE#GKC+F?'LDI,</!W,3=M(TB!+=L+A
MW%\I?OF70=C_ .S>ZL1Y&!)Q%+81$E4!%$GV]XV*WE@<TGBKXJBB@SVCI;B*
M=K@.&GCH:J,O9^KBYUWTX,PS)&PL<:&JPWW:B0 NPI3!7^1VLZ-)8/=MYFS*
M&#+Z*GSLH@K\-2K4F/'7#V['U.WQ!1+L"3(0,=M90;/&5;B  V -M@+;;8B
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M&MV$$P(",2FW%Z)98Y6,H0*&O2#T=FU0[>S,44D4CZ@D$4Z".GMV!<B+TMI
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M/DV*'81.N)#<S&O#L':!Z!Y=JN6U2*[53OV\?[W.SOZW@?UFS#5QDOT;3L]
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M-:R, @@+7UW^#;X5GMH;J-Y=//Q,IN\.SP*7KCC;+9NNF#330$XZZX0@VVV
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MO[JQJ85Q$CU]G55S4)Q;:LE5I./%%=!]48&3YH(D/DJ;;I\=89\@^XB=$Z,
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MIHW4^-US/;1:/N+*6*\?/(R&)D$C"Q[GRR%K8N$&HD+AP. <"" 5JOR.#XO
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#+__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
